<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CING="http://cingulate.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cing-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CING:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantsExercisableForOneShareOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CING:WarrantsExercisableForOneShareOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="From2024-10-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ClinicalOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:ClinicalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:ClinicalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DrugManufacturingAndFormulationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:DrugManufacturingAndFormulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DrugManufacturingAndFormulationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:DrugManufacturingAndFormulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PersonnelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:PersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PersonnelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:PersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RegulatoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:RegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RegulatoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:RegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LegalAndProfessionalFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:LegalAndProfessionalFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LegalAndProfessionalFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:LegalAndProfessionalFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_OccupancyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:OccupancyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OccupancyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:OccupancyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_InsuranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:InsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_InsuranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:InsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_OtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CING:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ConstructionInProgressEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CING:ConstructionInProgressEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ConstructionInProgressEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CING:ConstructionInProgressEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_custom_WerthFamilyInvestmentAssociatesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:WerthFamilyInvestmentAssociatesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-09_custom_WerthFamilyInvestmentAssociatesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:WerthFamilyInvestmentAssociatesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-09</instant>
        </period>
    </context>
    <context id="From2023-05-012023-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-08_custom_WerthFamilyInvestmentAssociatesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:WerthFamilyInvestmentAssociatesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="From2023-09-082023-09-08_custom_WerthFamilyInvestmentAssociatesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:WerthFamilyInvestmentAssociatesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-25_custom_WerthFamilyInvestmentAssociatesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:WerthFamilyInvestmentAssociatesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="From2024-01-252024-01-25_custom_WerthFamilyInvestmentAssociatesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:WerthFamilyInvestmentAssociatesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-25</startDate>
            <endDate>2024-01-25</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-20_custom_StreetvilleCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:StreetvilleCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-20</instant>
        </period>
    </context>
    <context id="From2025-07-022025-07-02_custom_StreetvilleCapitalLLCMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:StreetvilleCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-02</startDate>
            <endDate>2025-07-02</endDate>
        </period>
    </context>
    <context id="From2024-12-202024-12-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <startDate>2024-12-20</startDate>
            <endDate>2024-12-20</endDate>
        </period>
    </context>
    <context id="From2024-12-202024-12-20_custom_StreetvilleCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:StreetvilleCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-20</startDate>
            <endDate>2024-12-20</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_StreetvilleCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:StreetvilleCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WerthFamilyInvestmentAssociatesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:WerthFamilyInvestmentAssociatesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WerthFamilyInvestmentAssociatesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:WerthFamilyInvestmentAssociatesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StreetvilleCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:StreetvilleCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StreetvilleCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:StreetvilleCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OtherMember16236156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_OtherMember16236156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-11-302023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <startDate>2023-11-30</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="From2024-08-092024-08-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <startDate>2024-08-09</startDate>
            <endDate>2024-08-09</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="From2023-08-112023-08-11_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-11_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="AsOf2023-09-11_custom_SeriesAandSeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesAandSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-11</instant>
        </period>
    </context>
    <context id="AsOf2023-09-11_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-11</instant>
        </period>
    </context>
    <context id="From2023-09-112023-09-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <startDate>2023-09-11</startDate>
            <endDate>2023-09-11</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-02_custom_SeriesAandSeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CING:SeriesAandSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="AsOf2024-02-02_custom_PreFundedWarrantsMember_custom_SeriesAandSeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CING:SeriesAandSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="From2024-02-022024-02-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <startDate>2024-02-02</startDate>
            <endDate>2024-02-02</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-08_custom_WFIAPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:WFIAPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_WerthFamilyInvestmentAssociatesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:WerthFamilyInvestmentAssociatesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-28_custom_JuneTwentyTwentyFourWarrantsInducementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:JuneTwentyTwentyFourWarrantsInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="AsOf2024-06-28_custom_FebruaryTwentyTwentyFourWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:FebruaryTwentyTwentyFourWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="AsOf2024-06-28_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="AsOf2024-06-28_custom_SeriesDCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesDCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_JuneTwentyTwentyFourWarrantsInducementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:JuneTwentyTwentyFourWarrantsInducementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-04-30_custom_PurchaseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CING:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CING:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CING:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CING:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_custom_ATMAgreementMember_custom_HCWainwrightAndCoLLCMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CING:ATMAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_custom_ATMAgreementMember_custom_HCWainwrightAndCoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CING:ATMAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CING:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2024-03-172024-03-17_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-17</startDate>
            <endDate>2024-03-17</endDate>
        </period>
    </context>
    <context id="From2024-03-182024-03-18_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-18</startDate>
            <endDate>2024-03-18</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-02_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="AsOf2024-02-02_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="AsOf2024-02-02_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="From2024-08-182024-08-18_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-18</startDate>
            <endDate>2024-08-18</endDate>
        </period>
    </context>
    <context id="From2024-08-192024-08-19_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-19</startDate>
            <endDate>2024-08-19</endDate>
        </period>
    </context>
    <context id="From2024-09-022024-09-02_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-02</startDate>
            <endDate>2024-09-02</endDate>
        </period>
    </context>
    <context id="From2024-09-032024-09-03_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="From2024-10-142024-10-14_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-14</startDate>
            <endDate>2024-10-14</endDate>
        </period>
    </context>
    <context id="From2024-10-152024-10-15_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-15</startDate>
            <endDate>2024-10-15</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CING:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CING:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_SeriesAWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_SeriesBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesAandSeriesBWarrantsMember_custom_ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesAandSeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CING:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-02-02_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CING:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="From2024-02-052024-02-05_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="From2024-02-052024-02-05_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-02_custom_PreFundedWarrantsMember16237265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="AsOf2024-02-02_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="From2024-02-022024-02-02_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-02</startDate>
            <endDate>2024-02-02</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-02_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="AsOf2024-02-02_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="From2024-02-022024-02-02_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-02</startDate>
            <endDate>2024-02-02</endDate>
        </period>
    </context>
    <context id="From2024-02-022024-02-02_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-02</startDate>
            <endDate>2024-02-02</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-02_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="AsOf2024-02-02_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="AsOf2024-02-02_custom_SeriesCAndSeriesDWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeriesCAndSeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeptemberTwoThousandTwentyThreePublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeptemberTwoThousandTwentyThreePublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PreFundedWarrantsMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeptemberTwoThousandTwentyThreePublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CING:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeptemberTwoThousandTwentyThreePublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CING:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesABPlacementAgentWarrantsMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeptemberTwoThousandTwentyThreePublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CING:SeriesABPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesABPlacementAgentWarrantsMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeptemberTwoThousandTwentyThreePublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CING:SeriesABPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeptemberTwoThousandTwentyThreePublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeptemberTwoThousandTwentyThreePublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:FebruaryTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:FebruaryTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PreFundedWarrantsMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:FebruaryTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CING:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PreFundedWarrantsMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:FebruaryTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CING:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesABPlacementAgentWarrantsMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:FebruaryTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CING:SeriesABPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesABPlacementAgentWarrantsMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:FebruaryTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CING:SeriesABPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:FebruaryTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:FebruaryTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_DecemberTwoThousandTwentyOneUnderwriterWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:DecemberTwoThousandTwentyOneUnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_JuneTwoThousandTwentyFourSeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:JuneTwoThousandTwentyFourSeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_JuneTwoThousandTwentyFourSeriesDWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:JuneTwoThousandTwentyFourSeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_JulyTwoThousandTwentyFourPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CING:JulyTwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-05-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CING:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CING:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CING:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CING:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CING:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CING:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CING:TwoThousandAndTwentyOneEquityIncentivePlanPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CING:TwoThousandAndTwentyOneEquityIncentivePlanPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CING:TwoThousandAndTwentyOneEquityIncentivePlanPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CING:TwoThousandAndTwentyOneEquityIncentivePlanPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CING:TwoThousandAndTwentyOneEquityIncentivePlanPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CING:TwoThousandAndTwentyOneEquityIncentivePlanPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CING:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CING:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-06-30_custom_KansasCityOfficeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">CING:KansasCityOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_KansasCityOfficeMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">CING:KansasCityOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_KansasCityOfficeMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">CING:KansasCityOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_OfficeFacilitiesSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">CING:OfficeFacilitiesSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OperatingLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">CING:OperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OperatingLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">CING:OperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember16241843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember16241859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember_custom_PhaseThreeClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CING:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember_custom_NewDrugApplicationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CING:NewDrugApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember_custom_CTxOneThreeZeroOneAndCTxOneThreeZeroTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CING:CTxOneThreeZeroOneAndCTxOneThreeZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember_custom_CTxTwoOneZeroThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CING:CTxTwoOneZeroThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember_custom_CTxTwoOneZeoThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CING:CTxTwoOneZeoThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_WerthFamilyInvestmentAssociatesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CING:WerthFamilyInvestmentAssociatesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_DebtMember_custom_WerthFamilyInvestmentAssociatesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CING:WerthFamilyInvestmentAssociatesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_WerthFamilyInvestmentAssociatesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CING:WerthFamilyInvestmentAssociatesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CING:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-27</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_LincolnParkPurchaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001862150</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CING:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000004">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000006">0001862150</dei:EntityCentralIndexKey>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0127"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0129"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0163"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0164"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacementWithWfia
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacementWithWfia
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsSoldForCashInPublicOfferingNetOfFees
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsSoldForCashInPublicOfferingNetOfFees
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedValueWarrantInducement
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedValueWarrantInducement
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <CING:PrepaidDuesAndSubscriptions
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0602"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-01-012023-12-31_custom_StreetvilleCapitalLLCMember"
      id="xdx2ixbrl0752"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-02-052024-02-05_custom_SeriesAWarrantsMember"
      id="xdx2ixbrl0959">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-02-052024-02-05_custom_SeriesBWarrantsMember"
      id="xdx2ixbrl0961">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-02-022024-02-02_custom_PlacementAgentWarrantsMember"
      id="xdx2ixbrl0970">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-02-022024-02-02_custom_SeriesAWarrantsMember"
      id="xdx2ixbrl0973">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      id="xdx2ixbrl1126"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      id="xdx2ixbrl1144"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2019-06-30_custom_KansasCityOfficeMember"
      id="xdx2ixbrl1281">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-12-31_custom_OperatingLeaseMember"
      id="xdx2ixbrl1378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-12-31_custom_OperatingLeaseMember"
      id="xdx2ixbrl1380"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000013">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000014">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000015">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000016">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000018">001-40874</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000019">Cingulate Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000021">86-3825535</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000022">1901                                             W. 47th Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000023">Kansas     City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000024">KS</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000025">66205</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000026">(913)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000027">942-2300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000028">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000029">CING</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-01-012024-12-31_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000030">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_WarrantsExercisableForOneShareOfCommonStockMember"
      id="Fact000031">Warrants,     exercisable for one share of common stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_WarrantsExercisableForOneShareOfCommonStockMember"
      id="Fact000032">CINGW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-01-012024-12-31_custom_WarrantsExercisableForOneShareOfCommonStockMember"
      id="Fact000033">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000034">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000035">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000036">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000037">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000038">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000039">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000040">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2024-01-01to2024-12-31" id="Fact000041">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000042">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000043">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000044">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-30"
      decimals="-5"
      id="Fact000045"
      unitRef="USD">2000000.0</dei:EntityPublicFloat>
    <dei:EntityListingParValuePerShare
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000046"
      unitRef="USDPShares">0.0001</dei:EntityListingParValuePerShare>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-21"
      decimals="INF"
      id="Fact000047"
      unitRef="Shares">3768400</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000049">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000053">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Risk
Management and Strategy&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;Like
many of our peer companies, we recognize the significance of cybersecurity threats to our clients and operations. Our business strategy,
results of operations, and financial condition have not, to date, been affected by risks from cybersecurity threats. During the reporting
period, we have not experienced any material cyber incidents, nor have we experienced a series of immaterial incidents, which would require
disclosure.&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_zFjvaKi3thoi"&gt;In
the ordinary course of our business, we use, store and process data including data of our employees, partners, collaborators, and vendors.&lt;/span&gt;
To effectively prevent, detect, and respond to cybersecurity threats, we maintain a cyber risk management program, which is comprised
of a wide array of architecture and processes. The cyber risk management program falls under the responsibility of our &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240101__20241231_zM4AvCV9uwOg"&gt;Chief Financial
Officer&lt;/span&gt; who, in turn, manages our outsourced experts in IT and cyber security. Under the guidance of our Chief Financial Officer, we
task reputable &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zBRKWIctxQqh"&gt;third-party&lt;/span&gt; IT experts that utilize a wide variety of software to secure the environment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

We
have implemented a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity
threats to this data and our systems. We deploy a wide range of security tools across the environment including multifactor authentication,
data encryption, cloud-based backups, endpoint monitoring, and dark web monitoring. As a result, we have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zWBmoWOaSBJ7"&gt;not&lt;/span&gt; identified any material
cybersecurity risks and are continuously hardening our environment. Additionally, our program includes regular cybersecurity testing
for all employees.</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2024-01-01to2024-12-31" id="Fact000054">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="From2024-01-01to2024-12-31" id="Fact000055">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000056">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000057">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000058">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span&gt;Our
&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zFo80KDn6GVd"&gt;board of directors is responsible for the oversight of cybersecurity risk management&lt;/span&gt;. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240101__20241231_zflsUA9hv5Ye"&gt;The Chief Financial Officer reports to the board
of directors&lt;/span&gt;. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zM0UfrU9jri5"&gt;The Chief Financial Officer provides updates to the board of directors on our cybersecurity risk management program, including
any critical cybersecurity risks, ongoing cybersecurity initiatives and strategies, and applicable regulatory requirements and industry
standards on a regular basis.&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zvD1qxQQo5na"&gt;The Chief Financial Officer also notifies the board of directors of any cybersecurity incidents (suspected
or actual) and provides updates on the incidents as well as cybersecurity risk mitigation activities as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000059">board of directors is responsible for the oversight of cybersecurity risk management</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="From2024-01-01to2024-12-31" id="Fact000060">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000061">The Chief Financial Officer provides updates to the board of directors on our cybersecurity risk management program, including
any critical cybersecurity risks, ongoing cybersecurity initiatives and strategies, and applicable regulatory requirements and industry
standards on a regular basis.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000062">The Chief Financial Officer also notifies the board of directors of any cybersecurity incidents (suspected
or actual) and provides updates on the incidents as well as cybersecurity risk mitigation activities as appropriate.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact000063">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact000064">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact000065">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact000066">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000067">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000068">185</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000069">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000070">St. Louis, MO 63102-1761</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">12211321</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">52416</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">26325</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">14622</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">423157</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">511556</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">12660803</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">578594</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">2104675</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000091"
      unitRef="USD">2545965</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">99011</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000094"
      unitRef="USD">366877</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">14864489</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">3491436</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">1270280</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000106"
      unitRef="USD">5199105</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">1039625</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">1651519</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">2527108</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000112"
      unitRef="USD">3000000</us-gaap:NotesPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">4430</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">17057</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">130662</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000118"
      unitRef="USD">358085</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">4972105</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000121"
      unitRef="USD">10225766</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">2436879</us-gaap:LongTermNotesPayable>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000130"
      unitRef="USD">4436</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000133"
      unitRef="USD">130663</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000135"
      unitRef="USD">2436879</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000136"
      unitRef="USD">135099</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000138"
      unitRef="USD">7408984</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000139"
      unitRef="USD">10360865</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000147"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000149"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000151"
      unitRef="Shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000153"
      unitRef="Shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000155"
      unitRef="Shares">3402306</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000157"
      unitRef="Shares">3402306</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000159"
      unitRef="Shares">97293</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000161"
      unitRef="Shares">97293</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000144"
      unitRef="USD">340</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000145"
      unitRef="USD">10</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000166"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000168"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000172"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000174"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000178"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000180"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000182"
      unitRef="USD">115944345</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000183"
      unitRef="USD">86074004</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000185"
      unitRef="USD">-108489180</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000186"
      unitRef="USD">-92943443</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">7455505</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">-6869429</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">14864489</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">3491436</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">9445265</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">15493304</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">6199708</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">7265885</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000203"
      unitRef="USD">-15644973</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">-22759189</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000206"
      unitRef="USD">99236</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">-775758</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000209"
      unitRef="USD">-15545737</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">-23534947</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000215"
      unitRef="USD">-15545737</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">-23534947</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000218"
      unitRef="USDPShares">-10.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000220"
      unitRef="USDPShares">-10.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000222"
      unitRef="USDPShares">-311.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000224"
      unitRef="USDPShares">-311.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000226"
      unitRef="Shares">1524797</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000228"
      unitRef="Shares">1524797</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000230"
      unitRef="Shares">75435</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000232"
      unitRef="Shares">75435</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000240"
      unitRef="Shares">47123</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000234"
      unitRef="USD">5</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000235"
      unitRef="USD">73290513</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000236"
      unitRef="USD">-69408496</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000238"
      unitRef="USD">3882022</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000248"
      unitRef="Shares">10526</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000242"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000243"
      unitRef="USD">1840736</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">1840737</us-gaap:StockIssuedDuringPeriodValueOther>
    <CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacementWithWfiaShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000256"
      unitRef="Shares">7596</CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacementWithWfiaShares>
    <CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacementWithWfia
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000250"
      unitRef="USD">1</CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacementWithWfia>
    <CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacementWithWfia
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000251"
      unitRef="USD">999999</CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacementWithWfia>
    <CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacementWithWfia
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000254"
      unitRef="USD">1000000</CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacementWithWfia>
    <CING:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfFeesShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000264"
      unitRef="Shares">31952</CING:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInPublicOfferingNetOfFeesShares>
    <CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsSoldForCashInPublicOfferingNetOfFees
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000258"
      unitRef="USD">3</CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsSoldForCashInPublicOfferingNetOfFees>
    <CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsSoldForCashInPublicOfferingNetOfFees
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000259"
      unitRef="USD">3310548</CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsSoldForCashInPublicOfferingNetOfFees>
    <CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsSoldForCashInPublicOfferingNetOfFees
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000262"
      unitRef="USD">3310551</CING:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsSoldForCashInPublicOfferingNetOfFees>
    <CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000267"
      unitRef="USD">3949765</CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable>
    <CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000270"
      unitRef="USD">3949765</CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000273"
      unitRef="USD">1862735</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">1862735</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000284"
      unitRef="Shares">96</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">7038</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000282"
      unitRef="USD">7038</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000287"
      unitRef="USD">812670</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000290"
      unitRef="USD">812670</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">-23534947</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000296"
      unitRef="USD">-23534947</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000304"
      unitRef="Shares">97293</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000298"
      unitRef="USD">10</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000299"
      unitRef="USD">86074004</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000300"
      unitRef="USD">-92943443</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000302"
      unitRef="USD">-6869429</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000312"
      unitRef="Shares">97293</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000306"
      unitRef="USD">10</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000307"
      unitRef="USD">86074004</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000308"
      unitRef="USD">-92943443</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000310"
      unitRef="USD">-6869429</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000320"
      unitRef="Shares">130602</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <CING:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000314"
      unitRef="USD">13</CING:StockIssuedDuringPeriodValueReverseStockSplits>
    <CING:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000315"
      unitRef="USD">-13</CING:StockIssuedDuringPeriodValueReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000328"
      unitRef="Shares">2455456</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000322"
      unitRef="USD">245</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000323"
      unitRef="USD">17240466</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000326"
      unitRef="USD">17240711</us-gaap:StockIssuedDuringPeriodValueOther>
    <CING:StockIssuedSharesWarrantInducement
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000336"
      unitRef="Shares">265625</CING:StockIssuedSharesWarrantInducement>
    <CING:StockIssuedValueWarrantInducement
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000330"
      unitRef="USD">27</CING:StockIssuedValueWarrantInducement>
    <CING:StockIssuedValueWarrantInducement
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000331"
      unitRef="USD">1561400</CING:StockIssuedValueWarrantInducement>
    <CING:StockIssuedValueWarrantInducement
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000334"
      unitRef="USD">1561427</CING:StockIssuedValueWarrantInducement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000344"
      unitRef="Shares">296000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000338"
      unitRef="USD">30</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">6432862</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000342"
      unitRef="USD">6432892</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000347"
      unitRef="USD">2734739</CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable>
    <CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000350"
      unitRef="USD">2734739</CING:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedPartyNotePayable>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">586511</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000356"
      unitRef="USD">586511</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000364"
      unitRef="Shares">102832</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000358"
      unitRef="USD">10</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">-10</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000372"
      unitRef="Shares">54498</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000366"
      unitRef="USD">5</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000367"
      unitRef="USD">318916</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000370"
      unitRef="USD">318921</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000375"
      unitRef="USD">995470</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000378"
      unitRef="USD">995470</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000382"
      unitRef="USD">-15545737</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000384"
      unitRef="USD">-15545737</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000392"
      unitRef="Shares">3402306</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000386"
      unitRef="USD">340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000387"
      unitRef="USD">115944345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000388"
      unitRef="USD">-108489180</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000390"
      unitRef="USD">7455505</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000400"
      unitRef="Shares">3402306</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000394"
      unitRef="USD">340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000395"
      unitRef="USD">115944345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000396"
      unitRef="USD">-108489180</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000398"
      unitRef="USD">7455505</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000405"
      unitRef="USD">-15545737</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000406"
      unitRef="USD">-23534947</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000411"
      unitRef="USD">653090</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000412"
      unitRef="USD">582918</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000414"
      unitRef="USD">995484</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000415"
      unitRef="USD">812670</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000420"
      unitRef="USD">11703</us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000421"
      unitRef="USD">-219810</us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000423"
      unitRef="USD">-88399</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000424"
      unitRef="USD">-1767388</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <CING:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000426"
      unitRef="USD">-267886</CING:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <CING:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000427"
      unitRef="USD">-263741</CING:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000429"
      unitRef="USD">-4540719</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000430"
      unitRef="USD">5193632</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000432"
      unitRef="USD">-227424</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000433"
      unitRef="USD">18330</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <CING:IncreaseDecreaseInLongtermPortionOfOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000435"
      unitRef="USD">-130663</CING:IncreaseDecreaseInLongtermPortionOfOperatingLeaseLiability>
    <CING:IncreaseDecreaseInLongtermPortionOfOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000436"
      unitRef="USD">-358085</CING:IncreaseDecreaseInLongtermPortionOfOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000438"
      unitRef="USD">-18451387</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000439"
      unitRef="USD">-15034543</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000444"
      unitRef="USD">211800</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000445"
      unitRef="USD">224096</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000447"
      unitRef="USD">-211800</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000448"
      unitRef="USD">-224096</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000453"
      unitRef="USD">25875168</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000454"
      unitRef="USD">6970826</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000456"
      unitRef="USD">4963987</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000457"
      unitRef="USD">3000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000459"
      unitRef="USD">17063</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000460"
      unitRef="USD">16047</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000462"
      unitRef="USD">30822092</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000463"
      unitRef="USD">9954779</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000468"
      unitRef="USD">12158905</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000469"
      unitRef="USD">-5303860</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000471"
      unitRef="USD">52416</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000472"
      unitRef="USD">5356276</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000474"
      unitRef="USD">12211321</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000475"
      unitRef="USD">52416</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000480"
      unitRef="USD">31160</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000481"
      unitRef="USD">186960</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000486"
      unitRef="USD">6288</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000487"
      unitRef="USD">19421</us-gaap:InterestPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000489">&lt;p id="xdx_80C_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zpgYkdNbE7Yj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(1) &lt;span id="xdx_82A_zp2CfAFzUwQa"&gt;Nature
of the Business and Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cingulate
Inc. (Cingulate or the Company), a Delaware corporation, is a biopharmaceutical company focused on the development of products utilizing
its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with
an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). The Company is developing two proprietary, first-line
stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient
segments: children, adolescents, and adults. CTx-1301 and CTx-1302 utilize a flexible core tableting technology with target product profile
designed to deliver a rapid onset and last the entire active day with a controlled descent of plasma drug level and have favorable tolerability.
In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has incurred losses and negative cash flows from operations since inception. As a pre-revenue entity, the Company is dependent
on the ability to raise capital to support operations until such time as the product candidates under development are U.S. Food and Drug
Administration (FDA) approved, manufactured, commercially available to the marketplace and produce revenues. On December 31, 2024, the
Company had cash and cash equivalents of approximately $&lt;span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zaTVWQGH5hy9" title="Cash and cash equivalents"&gt;12.2&lt;/span&gt; million, and an accumulated deficit of approximately $&lt;span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_z38IWia3oKI4" title="Accumulated deficit"&gt;108.5&lt;/span&gt; million. However,
the Company will need additional funding for operations and development. Management is evaluating various strategies to obtain additional
funding, which may include additional offerings of equity, issuance of debt, or other capital sources, including potential collaborations
with other companies or other strategic transactions. Successful implementation of these plans involves both the Company&#x2019;s efforts
and factors that are outside its control, such as market factors and FDA approval of product candidates. The Company can give no assurance
that its plans will be effectively implemented in such a way that they will sufficiently alleviate or mitigate the conditions and events
noted above, which results in substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after
the date that the financial statements are issued. The accompanying consolidated financial statements have been prepared on a going concern
basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated
financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000491"
      unitRef="USD">12200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000493"
      unitRef="USD">-108500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000495">&lt;p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_zyth18eQuLv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(2)
&lt;span id="xdx_82B_znqMvPRvpD24"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zzHsByQBZsu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(a)
&lt;span id="xdx_86B_zgMb9HdmFty5"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S.
GAAP). The consolidated financial statements include the accounts of Cingulate and its wholly-owned subsidiaries. All intercompany accounts
and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--UseOfEstimates_z1hrKqVaU8kd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(b) &lt;span id="xdx_86D_zhwFUkuTLSUh"&gt;Use of
Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of expenses during a reporting period. Actual results could differ from estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimates
and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the
period they are determined to be necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zjgrPNWJ3utc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(c)
&lt;span id="xdx_868_z4zHavSzN7Bc"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company maintains cash equivalent deposits, which at various times throughout the fiscal year exceeded the amounts insured by the Federal
Deposit Insurance Corporation limit of $&lt;span id="xdx_905_eus-gaap--TimeDepositsAtOrAboveFDICInsuranceLimit_iI_c20241231_zG6jVYBF8Lri" title="Federal deposit insurance corporation limit"&gt;250,000&lt;/span&gt; (without regard to reconciling items). Management monitors the soundness of these financial
institutions and does not believe the Company is subject to any material credit risk relative to the uninsured portion of the deposits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8xRBUcVGD63" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(d)
&lt;span id="xdx_868_zjybEKPqmVqc"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting
pronouncement may affect the Company&#x2019;s financial reporting, the Company undertakes an analysis to determine any required changes
to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company&#x2019;s consolidated
financial statements properly reflect the change.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2024-03, &lt;i&gt;Income Statement
&#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures&lt;/i&gt; (Subtopic 220-40): Disaggregation of Income Statement
Expenses. ASU 2024-03 requires additional disclosures of certain expenses in the notes of the financial statements, to provide enhanced
transparency into the expense captions presented on the consolidated statements of operations. Additionally, in January 2025, the FASB
issued ASU 2025-01, &lt;i&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures&lt;/i&gt; (Subtopic 220-40),
to clarify the effective date of ASU 2024-03. The new standard is effective for the Company for its annual periods beginning January
1, 2028 and for interim periods beginning January 1, 2028, with early adoption permitted. The Company is currently evaluating the impact
of adopting the standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes &lt;/i&gt;(Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires
entities to disclose specific rate reconciliations, amount of income taxes separated by federal and individual jurisdiction, and the
amount of income (loss) from continuing operations before income tax expense (benefit) disaggregated between federal, state, and foreign.
The new standard is effective for the Company for its annual periods beginning January 1, 2026, with early adoption permitted. The Company
is currently evaluating the impact of adopting the standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
November 2023, the FASB issued ASU 2023-07, &lt;i&gt;Segment Reporting &lt;/i&gt;(Topic 280): Improvements to Reportable Segment Disclosures. ASU
2023-07 is designed to improve the reportable segment disclosure requirements, primarily through enhanced disclosures about significant
segment expenses that are regularly provided to the Company&#x2019;s chief operating decision&#x2013;making group (CODM). The new standard
is effective for the Company for its annual periods beginning January 1, 2024 and for interim periods beginning January 1, 2025, with
early adoption permitted. The Company adopted ASU 2023-07 on January 1, 2024, and the impacts of the adoption are reflected in the segment
disclosure section of the Summary of Significant Accounting Policies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCK1Qeg2BV53" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(e) &lt;span id="xdx_864_z0r0hTt6PgVd"&gt;Cash and
Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank
demand deposit accounts and short-term liquid investments with an initial maturity of three months or less are considered cash and cash
equivalents. Cash and cash equivalents as of December 31, 2024 and 2023 consisted of bank deposits and short-term money market funds.
Cash and cash equivalents are carried at cost which is indicative of fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zpA6prOxqeG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(f) &lt;span id="xdx_86A_z46Jfy6Ud3p4"&gt;Property
and Equipment, net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
and equipment, net are stated at cost, less accumulated depreciation. Maintenance and repairs are charged to expense when incurred. Property
and equipment are depreciated using the straight-line method over the estimated remaining useful lives or, for leasehold improvements
or leased assets under a financing lease, the life of the lease if shorter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zGlwpr5j2p7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(g) &lt;span id="xdx_867_zURaw3iNe5ha"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company is a lessee in a noncancellable operating lease, relating to office space at the Kansas City headquarters office and a finance
lease, for certain furniture and equipment. The Company also leased office space in New Jersey under an operating lease which expired
on December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company determines if an arrangement is or contains a lease at contract inception. The Company recognizes a ROU asset and a lease liability
at the lease commencement date. For operating leases, the lease liability is initially and subsequently measured at the present value
of the unpaid lease payments at the lease commencement date. For finance leases, the lease liability is initially measured in the same
manner and date as for operating leases and is subsequently measured at amortized cost using the effective-interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company determines the discount rate it uses to discount the unpaid lease payments to present value, which requires management judgement.
ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot
be readily determined, its incremental borrowing rate. The implicit rate was stated in the agreement for one of the Company&#x2019;s leases;
however, for the others, the implicit rate was not determinable as the Company did not have access to the lessor&#x2019;s estimated residual
value or the amount of the lessor&#x2019;s deferred initial direct costs. Therefore, the Company uses its incremental borrowing rate as
the discount rate for these leases. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would have
to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Because the Company has not been
able to borrow on a collateralized basis, it has determined a synthetic credit rating based on factors that a credit rating agency would
typically analyze when establishing an entity&#x2019;s credit rating. Due to the fact that the Company is a pre-revenue entity, the Company
determined that its incremental borrowing rate should be based on the composite CCC and lower bond spreads at the lease measurement dates
plus a risk-free rate based on specific lease maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at
or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus
initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of cumulative lease incentives
received. Lease expense is recognized on a straight-line basis over the lease term which includes the accretion of the lease liability
and amortization of the ROU asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier
of the end of its useful life or the end of the lease term unless the lease transfers ownerships of the underlying asset to the Company
or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized
over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense
on the lease liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;ROU
assets for operating and finance leases are evaluated for impairment losses under the long-lived assets impairment guidance in ASC Subtopic
360-10, &lt;i&gt;Property and Equipment-Overall&lt;/i&gt;. The ROU asset is assessed for impairment with the asset group within which it resides.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
lease ROU assets are presented as operating lease right-of-use assets on the consolidated balance sheet. The current and long-term portions
of operating lease liabilities are presented separately on the consolidated balance sheet. Finance lease ROU assets are included in property,
plant, and equipment. The current and long-term portions of finance lease liabilities are presented separately on the consolidated balance
sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zlh3vN74wgMb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(h)
&lt;span id="xdx_868_zfCbVPIYTS2"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company assesses the carrying value of its long-lived assets, including property and equipment, as well as lease ROU assets, when events
or circumstances indicate that the carrying value of such assets may not be recoverable. These events or changes in circumstances may
include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If
an impairment indicator is present, the Company evaluates recoverability by a comparison of the carrying amount of the assets to future
undiscounted cash flows expected to be generated by the assets. If the sum of the expected future cash flows is less than the carrying
amount, the Company would recognize an impairment loss. An impairment loss would be measured by comparing the amount by which the carrying
value exceeds the fair value of the long-lived asset groups. No impairment was recognized during the years ended December 31, 2024 or
2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_z6yReqAp0afe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(i) &lt;span id="xdx_868_zLpB8BsQ8b1a"&gt;Research
and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
and development costs are expensed as incurred and include all direct and indirect costs associated with the development of the Company&#x2019;s
product candidates. These expenses include payments to third parties for research, development and manufacturing services, personnel
costs and depreciation on manufacturing equipment. At the end of the reporting period, the Company compares payments made to third party
service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to
change as additional information becomes available. Depending on the timing of payments to service providers and the progress that the
Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to
these costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zgOnPtjW7dPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(j) &lt;span id="xdx_867_zxbpr1cLej01"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value
using the Black-Scholes option-pricing model. For stock-based awards with service conditions, stock-based compensation expense is recognized
over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. See additional information
in Note 12.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkBP3RKHaH3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(k) &lt;span id="xdx_86C_z8Q2R1P9e1ug"&gt;Segments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
segments are defined as components of an enterprise for which discrete financial information is available and regularly reviewed by the
chief operating decision maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources and in assessing performance. The Company manages
its business activities on a consolidated basis and operates as a single operating segment dedicated to the research and development
and manufacturing of its product candidates. The Company&#x2019;s CODM is its Chief Executive Officer. The CODM uses net loss, as reported
in the Company&#x2019;s Consolidated Statements of Comprehensive Loss, in evaluating performance of its segment and determining how to
allocate resources of the Company as a whole, including investing in its research and development activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
measure used by the CODM for segment assets is reported in the Consolidated Balance Sheets as total consolidated assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zf6mLchjggFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table presents the operating results of the Company&#x2019;s segment:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B4_zILutMvgKTX3"&gt;Schedule
of operating results of company&#x2019;s segment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-indent: 0pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_495_20240101__20241231_zgau8JIHXY3" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20230101__20231231_zGLTUwxI1Qng" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_z0bO78Hjvjrj" style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    expenses:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_z1c8rnRXw7Bk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ClinicalOperationsMember_zv9PlnU6xTdf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; width: 60%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Clinical
    operations&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,711,745&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 16%"&gt;8,344,759&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--DrugManufacturingAndFormulationMember_zIRFUIc9TWF5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Drug
    manufacturing and formulation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,695,896&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,351,542&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--PersonnelMember_zK1XQzxW9Aqe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Personnel&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,761,558&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,438,108&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--RegulatoryMember_z7OLcwNfKSi5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regulatory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;276,066&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;358,895&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_msOILzF0H_zupcRyiPqwUc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,445,265&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;15,493,304&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__custom--PersonnelMember_zUBDMWgUBp6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Personnel&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,862,356&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,643,726&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__custom--LegalAndProfessionalFeesMember_zcEzcTBcADpb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Legal
    and professional fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,396,063&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,942,624&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__us-gaap--OccupancyMember_zCLYUxnrAp5b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Occupancy&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;345,535&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;495,732&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__custom--InsuranceMember_zmMP7QAH30ed" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;983,758&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,543,060&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__custom--OtherMember_zEG85lliHUYe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;611,996&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;640,743&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i01_msOILzF0H_z0X7y9Pk4U36" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,199,708&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,265,885&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingIncomeLoss_i01T_mtOILzF0H_maILFCOz6ut_zoMHJHPtqerc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    loss&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,644,973&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(22,759,189&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_maILFCOz6ut_zpbeyYRERZp4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest
    and other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99,236&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(775,758&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOz6ut_maNILzzFO_zdGdTxOfnOVe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,545,737&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(23,534,947&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_msNILzzFO_z4QEqGotVe5k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0571"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0572"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_iT_mtNILzzFO_zf2vRlDCsHdh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,545,737&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(23,534,947&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zhoER9sP6JNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zRaVC8yVDLg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(l) &lt;span id="xdx_867_zG29HhPdnowb"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cingulate
Inc. is taxed as a C corporation under the Internal Revenue Code. Cingulate Inc. records deferred income taxes to reflect the impact
of temporary differences between the recorded amounts of assets and liabilities for financial reporting purposes and such amounts as
measured by tax laws and regulations. As of December 31, 2024, Cingulate Therapeutics LLC (CTx) is a wholly-owned disregarded entity
of Cingulate Inc., and all of the activity for CTx, along with its wholly-owned subsidiary Cingulate Works Inc., is included in the calculation
of the current and deferred tax assets and liabilities for Cingulate Inc. The Company determined that it was more likely than not that
it would not realize its deferred tax assets, based on historical levels of income and future forecasts of taxable income, among other
items, therefore a full valuation allowance is recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has not identified any uncertain tax positions. There have been no interest or penalties recognized in the consolidated financial
statements related to uncertain tax positions. In addition, no tax positions exist for which it is reasonably possible that the total
amounts of unrecognized tax benefits will significantly increase or decrease within the next 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company files income tax returns in the federal and various state jurisdictions. These federal income taxes are immaterial. The Company
is no longer subject to U.S. federal income tax examinations by tax authorities for years before 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--CommonStockPurchaseWarrantsPolicyTextBlock_zpqeM3QhZUH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(m) &lt;span id="xdx_863_zAHZoKFgQvga"&gt;Common
Stock Purchase Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company issued warrants in connection with its IPO in December 2021, common stock offerings in September 2023 and February 2024, and
a warrant inducement in June 2024. These equity instruments were valued at fair value when they were issued. See additional information
in Note 11.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zqLuSYgDsD3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(n) &lt;span id="xdx_868_zTK8WMyAmTgg"&gt;Net Loss
per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period,
without consideration to potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the
sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive instruments outstanding
during the period using the simplified method. Diluted net loss per share is the same as basic net loss per share since the effect of
all outstanding potentially dilutive securities is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_855_zjMcCELfj41" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000497">&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zzHsByQBZsu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(a)
&lt;span id="xdx_86B_zgMb9HdmFty5"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S.
GAAP). The consolidated financial statements include the accounts of Cingulate and its wholly-owned subsidiaries. All intercompany accounts
and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000499">&lt;p id="xdx_844_eus-gaap--UseOfEstimates_z1hrKqVaU8kd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(b) &lt;span id="xdx_86D_zhwFUkuTLSUh"&gt;Use of
Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of expenses during a reporting period. Actual results could differ from estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimates
and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the
period they are determined to be necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-12-31" id="Fact000501">&lt;p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zjgrPNWJ3utc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(c)
&lt;span id="xdx_868_z4zHavSzN7Bc"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company maintains cash equivalent deposits, which at various times throughout the fiscal year exceeded the amounts insured by the Federal
Deposit Insurance Corporation limit of $&lt;span id="xdx_905_eus-gaap--TimeDepositsAtOrAboveFDICInsuranceLimit_iI_c20241231_zG6jVYBF8Lri" title="Federal deposit insurance corporation limit"&gt;250,000&lt;/span&gt; (without regard to reconciling items). Management monitors the soundness of these financial
institutions and does not believe the Company is subject to any material credit risk relative to the uninsured portion of the deposits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000503"
      unitRef="USD">250000</us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000505">&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8xRBUcVGD63" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(d)
&lt;span id="xdx_868_zjybEKPqmVqc"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting
pronouncement may affect the Company&#x2019;s financial reporting, the Company undertakes an analysis to determine any required changes
to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company&#x2019;s consolidated
financial statements properly reflect the change.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2024-03, &lt;i&gt;Income Statement
&#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures&lt;/i&gt; (Subtopic 220-40): Disaggregation of Income Statement
Expenses. ASU 2024-03 requires additional disclosures of certain expenses in the notes of the financial statements, to provide enhanced
transparency into the expense captions presented on the consolidated statements of operations. Additionally, in January 2025, the FASB
issued ASU 2025-01, &lt;i&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures&lt;/i&gt; (Subtopic 220-40),
to clarify the effective date of ASU 2024-03. The new standard is effective for the Company for its annual periods beginning January
1, 2028 and for interim periods beginning January 1, 2028, with early adoption permitted. The Company is currently evaluating the impact
of adopting the standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes &lt;/i&gt;(Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires
entities to disclose specific rate reconciliations, amount of income taxes separated by federal and individual jurisdiction, and the
amount of income (loss) from continuing operations before income tax expense (benefit) disaggregated between federal, state, and foreign.
The new standard is effective for the Company for its annual periods beginning January 1, 2026, with early adoption permitted. The Company
is currently evaluating the impact of adopting the standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
November 2023, the FASB issued ASU 2023-07, &lt;i&gt;Segment Reporting &lt;/i&gt;(Topic 280): Improvements to Reportable Segment Disclosures. ASU
2023-07 is designed to improve the reportable segment disclosure requirements, primarily through enhanced disclosures about significant
segment expenses that are regularly provided to the Company&#x2019;s chief operating decision&#x2013;making group (CODM). The new standard
is effective for the Company for its annual periods beginning January 1, 2024 and for interim periods beginning January 1, 2025, with
early adoption permitted. The Company adopted ASU 2023-07 on January 1, 2024, and the impacts of the adoption are reflected in the segment
disclosure section of the Summary of Significant Accounting Policies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000507">&lt;p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCK1Qeg2BV53" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(e) &lt;span id="xdx_864_z0r0hTt6PgVd"&gt;Cash and
Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank
demand deposit accounts and short-term liquid investments with an initial maturity of three months or less are considered cash and cash
equivalents. Cash and cash equivalents as of December 31, 2024 and 2023 consisted of bank deposits and short-term money market funds.
Cash and cash equivalents are carried at cost which is indicative of fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000509">&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zpA6prOxqeG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(f) &lt;span id="xdx_86A_z46Jfy6Ud3p4"&gt;Property
and Equipment, net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
and equipment, net are stated at cost, less accumulated depreciation. Maintenance and repairs are charged to expense when incurred. Property
and equipment are depreciated using the straight-line method over the estimated remaining useful lives or, for leasehold improvements
or leased assets under a financing lease, the life of the lease if shorter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000511">&lt;p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zGlwpr5j2p7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(g) &lt;span id="xdx_867_zURaw3iNe5ha"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company is a lessee in a noncancellable operating lease, relating to office space at the Kansas City headquarters office and a finance
lease, for certain furniture and equipment. The Company also leased office space in New Jersey under an operating lease which expired
on December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company determines if an arrangement is or contains a lease at contract inception. The Company recognizes a ROU asset and a lease liability
at the lease commencement date. For operating leases, the lease liability is initially and subsequently measured at the present value
of the unpaid lease payments at the lease commencement date. For finance leases, the lease liability is initially measured in the same
manner and date as for operating leases and is subsequently measured at amortized cost using the effective-interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company determines the discount rate it uses to discount the unpaid lease payments to present value, which requires management judgement.
ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot
be readily determined, its incremental borrowing rate. The implicit rate was stated in the agreement for one of the Company&#x2019;s leases;
however, for the others, the implicit rate was not determinable as the Company did not have access to the lessor&#x2019;s estimated residual
value or the amount of the lessor&#x2019;s deferred initial direct costs. Therefore, the Company uses its incremental borrowing rate as
the discount rate for these leases. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would have
to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Because the Company has not been
able to borrow on a collateralized basis, it has determined a synthetic credit rating based on factors that a credit rating agency would
typically analyze when establishing an entity&#x2019;s credit rating. Due to the fact that the Company is a pre-revenue entity, the Company
determined that its incremental borrowing rate should be based on the composite CCC and lower bond spreads at the lease measurement dates
plus a risk-free rate based on specific lease maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at
or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus
initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of cumulative lease incentives
received. Lease expense is recognized on a straight-line basis over the lease term which includes the accretion of the lease liability
and amortization of the ROU asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier
of the end of its useful life or the end of the lease term unless the lease transfers ownerships of the underlying asset to the Company
or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized
over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense
on the lease liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;ROU
assets for operating and finance leases are evaluated for impairment losses under the long-lived assets impairment guidance in ASC Subtopic
360-10, &lt;i&gt;Property and Equipment-Overall&lt;/i&gt;. The ROU asset is assessed for impairment with the asset group within which it resides.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
lease ROU assets are presented as operating lease right-of-use assets on the consolidated balance sheet. The current and long-term portions
of operating lease liabilities are presented separately on the consolidated balance sheet. Finance lease ROU assets are included in property,
plant, and equipment. The current and long-term portions of finance lease liabilities are presented separately on the consolidated balance
sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000513">&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zlh3vN74wgMb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(h)
&lt;span id="xdx_868_zfCbVPIYTS2"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company assesses the carrying value of its long-lived assets, including property and equipment, as well as lease ROU assets, when events
or circumstances indicate that the carrying value of such assets may not be recoverable. These events or changes in circumstances may
include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If
an impairment indicator is present, the Company evaluates recoverability by a comparison of the carrying amount of the assets to future
undiscounted cash flows expected to be generated by the assets. If the sum of the expected future cash flows is less than the carrying
amount, the Company would recognize an impairment loss. An impairment loss would be measured by comparing the amount by which the carrying
value exceeds the fair value of the long-lived asset groups. No impairment was recognized during the years ended December 31, 2024 or
2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000515">&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_z6yReqAp0afe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(i) &lt;span id="xdx_868_zLpB8BsQ8b1a"&gt;Research
and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
and development costs are expensed as incurred and include all direct and indirect costs associated with the development of the Company&#x2019;s
product candidates. These expenses include payments to third parties for research, development and manufacturing services, personnel
costs and depreciation on manufacturing equipment. At the end of the reporting period, the Company compares payments made to third party
service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to
change as additional information becomes available. Depending on the timing of payments to service providers and the progress that the
Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to
these costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000517">&lt;p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zgOnPtjW7dPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(j) &lt;span id="xdx_867_zxbpr1cLej01"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value
using the Black-Scholes option-pricing model. For stock-based awards with service conditions, stock-based compensation expense is recognized
over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. See additional information
in Note 12.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000519">&lt;p id="xdx_847_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkBP3RKHaH3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(k) &lt;span id="xdx_86C_z8Q2R1P9e1ug"&gt;Segments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
segments are defined as components of an enterprise for which discrete financial information is available and regularly reviewed by the
chief operating decision maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources and in assessing performance. The Company manages
its business activities on a consolidated basis and operates as a single operating segment dedicated to the research and development
and manufacturing of its product candidates. The Company&#x2019;s CODM is its Chief Executive Officer. The CODM uses net loss, as reported
in the Company&#x2019;s Consolidated Statements of Comprehensive Loss, in evaluating performance of its segment and determining how to
allocate resources of the Company as a whole, including investing in its research and development activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
measure used by the CODM for segment assets is reported in the Consolidated Balance Sheets as total consolidated assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zf6mLchjggFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table presents the operating results of the Company&#x2019;s segment:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B4_zILutMvgKTX3"&gt;Schedule
of operating results of company&#x2019;s segment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-indent: 0pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_495_20240101__20241231_zgau8JIHXY3" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20230101__20231231_zGLTUwxI1Qng" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_z0bO78Hjvjrj" style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    expenses:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_z1c8rnRXw7Bk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ClinicalOperationsMember_zv9PlnU6xTdf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; width: 60%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Clinical
    operations&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,711,745&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 16%"&gt;8,344,759&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--DrugManufacturingAndFormulationMember_zIRFUIc9TWF5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Drug
    manufacturing and formulation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,695,896&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,351,542&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--PersonnelMember_zK1XQzxW9Aqe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Personnel&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,761,558&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,438,108&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--RegulatoryMember_z7OLcwNfKSi5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regulatory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;276,066&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;358,895&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_msOILzF0H_zupcRyiPqwUc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,445,265&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;15,493,304&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__custom--PersonnelMember_zUBDMWgUBp6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Personnel&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,862,356&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,643,726&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__custom--LegalAndProfessionalFeesMember_zcEzcTBcADpb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Legal
    and professional fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,396,063&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,942,624&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__us-gaap--OccupancyMember_zCLYUxnrAp5b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Occupancy&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;345,535&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;495,732&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__custom--InsuranceMember_zmMP7QAH30ed" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;983,758&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,543,060&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__custom--OtherMember_zEG85lliHUYe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;611,996&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;640,743&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i01_msOILzF0H_z0X7y9Pk4U36" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,199,708&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,265,885&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingIncomeLoss_i01T_mtOILzF0H_maILFCOz6ut_zoMHJHPtqerc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    loss&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,644,973&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(22,759,189&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_maILFCOz6ut_zpbeyYRERZp4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest
    and other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99,236&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(775,758&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOz6ut_maNILzzFO_zdGdTxOfnOVe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,545,737&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(23,534,947&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_msNILzzFO_z4QEqGotVe5k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0571"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0572"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_iT_mtNILzzFO_zf2vRlDCsHdh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,545,737&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(23,534,947&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zhoER9sP6JNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000521">&lt;p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zf6mLchjggFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table presents the operating results of the Company&#x2019;s segment:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B4_zILutMvgKTX3"&gt;Schedule
of operating results of company&#x2019;s segment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-indent: 0pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_495_20240101__20241231_zgau8JIHXY3" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49A_20230101__20231231_zGLTUwxI1Qng" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_z0bO78Hjvjrj" style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    expenses:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpenseAbstract_iB_z1c8rnRXw7Bk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ClinicalOperationsMember_zv9PlnU6xTdf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; width: 60%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Clinical
    operations&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,711,745&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 16%"&gt;8,344,759&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--DrugManufacturingAndFormulationMember_zIRFUIc9TWF5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Drug
    manufacturing and formulation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,695,896&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,351,542&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--PersonnelMember_zK1XQzxW9Aqe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Personnel&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,761,558&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,438,108&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--RegulatoryMember_z7OLcwNfKSi5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regulatory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;276,066&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;358,895&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_msOILzF0H_zupcRyiPqwUc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,445,265&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;15,493,304&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__custom--PersonnelMember_zUBDMWgUBp6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Personnel&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,862,356&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,643,726&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__custom--LegalAndProfessionalFeesMember_zcEzcTBcADpb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Legal
    and professional fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,396,063&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,942,624&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__us-gaap--OccupancyMember_zCLYUxnrAp5b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Occupancy&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;345,535&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;495,732&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__custom--InsuranceMember_zmMP7QAH30ed" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;983,758&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,543,060&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--ProductOrServiceAxis__custom--OtherMember_zEG85lliHUYe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;611,996&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;640,743&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i01_msOILzF0H_z0X7y9Pk4U36" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,199,708&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,265,885&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingIncomeLoss_i01T_mtOILzF0H_maILFCOz6ut_zoMHJHPtqerc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    loss&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,644,973&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(22,759,189&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_maILFCOz6ut_zpbeyYRERZp4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest
    and other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99,236&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(775,758&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOz6ut_maNILzzFO_zdGdTxOfnOVe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,545,737&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(23,534,947&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_msNILzzFO_z4QEqGotVe5k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0571"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0572"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_iT_mtNILzzFO_zf2vRlDCsHdh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,545,737&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(23,534,947&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_ClinicalOperationsMember"
      decimals="0"
      id="Fact000529"
      unitRef="USD">4711745</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_ClinicalOperationsMember"
      decimals="0"
      id="Fact000530"
      unitRef="USD">8344759</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_DrugManufacturingAndFormulationMember"
      decimals="0"
      id="Fact000532"
      unitRef="USD">2695896</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_DrugManufacturingAndFormulationMember"
      decimals="0"
      id="Fact000533"
      unitRef="USD">4351542</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_PersonnelMember"
      decimals="0"
      id="Fact000535"
      unitRef="USD">1761558</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_PersonnelMember"
      decimals="0"
      id="Fact000536"
      unitRef="USD">2438108</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_RegulatoryMember"
      decimals="0"
      id="Fact000538"
      unitRef="USD">276066</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_RegulatoryMember"
      decimals="0"
      id="Fact000539"
      unitRef="USD">358895</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000541"
      unitRef="USD">9445265</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000542"
      unitRef="USD">15493304</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_PersonnelMember"
      decimals="0"
      id="Fact000544"
      unitRef="USD">1862356</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_custom_PersonnelMember"
      decimals="0"
      id="Fact000545"
      unitRef="USD">2643726</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_LegalAndProfessionalFeesMember"
      decimals="0"
      id="Fact000547"
      unitRef="USD">2396063</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_custom_LegalAndProfessionalFeesMember"
      decimals="0"
      id="Fact000548"
      unitRef="USD">1942624</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OccupancyMember"
      decimals="0"
      id="Fact000550"
      unitRef="USD">345535</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OccupancyMember"
      decimals="0"
      id="Fact000551"
      unitRef="USD">495732</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_InsuranceMember"
      decimals="0"
      id="Fact000553"
      unitRef="USD">983758</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_custom_InsuranceMember"
      decimals="0"
      id="Fact000554"
      unitRef="USD">1543060</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_OtherMember"
      decimals="0"
      id="Fact000556"
      unitRef="USD">611996</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_custom_OtherMember"
      decimals="0"
      id="Fact000557"
      unitRef="USD">640743</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000559"
      unitRef="USD">6199708</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000560"
      unitRef="USD">7265885</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000562"
      unitRef="USD">-15644973</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000563"
      unitRef="USD">-22759189</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000565"
      unitRef="USD">99236</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000566"
      unitRef="USD">-775758</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000568"
      unitRef="USD">-15545737</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000569"
      unitRef="USD">-23534947</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000574"
      unitRef="USD">-15545737</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000575"
      unitRef="USD">-23534947</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000577">&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zRaVC8yVDLg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(l) &lt;span id="xdx_867_zG29HhPdnowb"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cingulate
Inc. is taxed as a C corporation under the Internal Revenue Code. Cingulate Inc. records deferred income taxes to reflect the impact
of temporary differences between the recorded amounts of assets and liabilities for financial reporting purposes and such amounts as
measured by tax laws and regulations. As of December 31, 2024, Cingulate Therapeutics LLC (CTx) is a wholly-owned disregarded entity
of Cingulate Inc., and all of the activity for CTx, along with its wholly-owned subsidiary Cingulate Works Inc., is included in the calculation
of the current and deferred tax assets and liabilities for Cingulate Inc. The Company determined that it was more likely than not that
it would not realize its deferred tax assets, based on historical levels of income and future forecasts of taxable income, among other
items, therefore a full valuation allowance is recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has not identified any uncertain tax positions. There have been no interest or penalties recognized in the consolidated financial
statements related to uncertain tax positions. In addition, no tax positions exist for which it is reasonably possible that the total
amounts of unrecognized tax benefits will significantly increase or decrease within the next 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company files income tax returns in the federal and various state jurisdictions. These federal income taxes are immaterial. The Company
is no longer subject to U.S. federal income tax examinations by tax authorities for years before 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <CING:CommonStockPurchaseWarrantsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000579">&lt;p id="xdx_840_ecustom--CommonStockPurchaseWarrantsPolicyTextBlock_zpqeM3QhZUH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(m) &lt;span id="xdx_863_zAHZoKFgQvga"&gt;Common
Stock Purchase Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company issued warrants in connection with its IPO in December 2021, common stock offerings in September 2023 and February 2024, and
a warrant inducement in June 2024. These equity instruments were valued at fair value when they were issued. See additional information
in Note 11.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CING:CommonStockPurchaseWarrantsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000581">&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zqLuSYgDsD3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(n) &lt;span id="xdx_868_zTK8WMyAmTgg"&gt;Net Loss
per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period,
without consideration to potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the
sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive instruments outstanding
during the period using the simplified method. Diluted net loss per share is the same as basic net loss per share since the effect of
all outstanding potentially dilutive securities is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <CING:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000583">&lt;p id="xdx_800_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_zUALZGgAr0eh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(3) &lt;span id="xdx_82A_zOFcndelfvef"&gt;Prepaid
Expenses and Other Current Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zZRBa7tHl0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid
expenses and other current assets consisted of the following at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_z29wRITzWwE4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Prepaid Expenses&#160;and Other Current Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zC42JOyXi2s6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_zam1bxiPGJ14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PrepaidResearchAndDevelopment_iI_maPECzL08_zgpujTwzSZxd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;334,692&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183,452&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPECzL08_zjvjbjUb1Mo5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54,865&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,698&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--PrepaidActivePharmaceuticalIngredients_iI_maPECzL08_zwRUcdZh1Ym3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Active pharmaceutical ingredients&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,324&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PrepaidDuesAndSubscriptions_iI_maPECzL08_zIXSIfJGHJEe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dues and subscriptions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,575&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0597"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredOfferingCosts_iI_maPECzL08_z8jsgdob2ir4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred capital raise costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;178,780&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PrepaidInsurance_iI_maPECzL08_zw6KORV6kNJi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0602"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,302&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPECzL08_z5Ns5Ww23S11" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total prepaid expenses
    and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;423,157&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;511,556&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zdZMibgKqDUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CING:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000585">&lt;p id="xdx_89F_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zZRBa7tHl0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid
expenses and other current assets consisted of the following at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_z29wRITzWwE4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Prepaid Expenses&#160;and Other Current Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zC42JOyXi2s6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_zam1bxiPGJ14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PrepaidResearchAndDevelopment_iI_maPECzL08_zgpujTwzSZxd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;334,692&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183,452&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPECzL08_zjvjbjUb1Mo5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54,865&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,698&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--PrepaidActivePharmaceuticalIngredients_iI_maPECzL08_zwRUcdZh1Ym3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Active pharmaceutical ingredients&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,324&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PrepaidDuesAndSubscriptions_iI_maPECzL08_zIXSIfJGHJEe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dues and subscriptions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,575&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0597"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredOfferingCosts_iI_maPECzL08_z8jsgdob2ir4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred capital raise costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;178,780&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PrepaidInsurance_iI_maPECzL08_zw6KORV6kNJi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0602"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,302&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPECzL08_z5Ns5Ww23S11" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total prepaid expenses
    and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;423,157&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;511,556&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <CING:PrepaidResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000587"
      unitRef="USD">334692</CING:PrepaidResearchAndDevelopment>
    <CING:PrepaidResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000588"
      unitRef="USD">183452</CING:PrepaidResearchAndDevelopment>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000590"
      unitRef="USD">54865</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000591"
      unitRef="USD">20698</us-gaap:OtherPrepaidExpenseCurrent>
    <CING:PrepaidActivePharmaceuticalIngredients
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000593"
      unitRef="USD">29025</CING:PrepaidActivePharmaceuticalIngredients>
    <CING:PrepaidActivePharmaceuticalIngredients
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000594"
      unitRef="USD">97324</CING:PrepaidActivePharmaceuticalIngredients>
    <CING:PrepaidDuesAndSubscriptions
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000596"
      unitRef="USD">4575</CING:PrepaidDuesAndSubscriptions>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000600"
      unitRef="USD">178780</us-gaap:DeferredOfferingCosts>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000603"
      unitRef="USD">31302</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000605"
      unitRef="USD">423157</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000606"
      unitRef="USD">511556</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000608">&lt;p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zR2X94Lfg2Cg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(4)
&lt;span id="xdx_824_zEIp8Dh112mb"&gt;Property and Equipment, net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5DotUvR5sE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
and equipment, net consisted of the following at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zjyiKmz9MlV7" style="display: none"&gt;Schedule of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Estimated&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20241231_zmk4g2iri1Vg"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20231231_zopabRg7aR1l"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zOmc3fFHAxx9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_z0Jxqe2glfS2" title="Property and equipment, estimated useful life"&gt;2&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zpAzy8DYpM6a" title="Property and equipment, estimated useful life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,358,261&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,321,816&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zrB2JGwUYSye" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z3APahcsFgU1" title="Property and equipment, estimated useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zxmRKKC9Tds9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zsWPqsOKmF86" title="Property and equipment, estimated useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,898&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zbQMqJY34k6h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z0Eece87vQx7" title="Property and equipment, estimated useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;474,462&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;471,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ConstructionInProgressEquipmentMember_z7qpdWZuBNfj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Construction-in-process- equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;375,278&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;207,976&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzeQW_zjxFuMf7cDIi" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,400,749&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,188,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzeQW_zs4CDjS0ABh5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,296,074&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,642,984&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzeQW_zG2UZQJQb5d8" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,104,675&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,545,965&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AC_zWdPvguGvld4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation
expense was $&lt;span id="xdx_907_eus-gaap--Depreciation_c20240101__20241231_zBnOX8re3zn4" title="Depreciation expense"&gt;653,090&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--Depreciation_c20230101__20231231_zi3VyjDeuryh" title="Depreciation expense"&gt;582,918&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000610">&lt;p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_z5DotUvR5sE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
and equipment, net consisted of the following at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zjyiKmz9MlV7" style="display: none"&gt;Schedule of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Estimated&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20241231_zmk4g2iri1Vg"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20231231_zopabRg7aR1l"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zOmc3fFHAxx9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_z0Jxqe2glfS2" title="Property and equipment, estimated useful life"&gt;2&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zpAzy8DYpM6a" title="Property and equipment, estimated useful life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,358,261&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,321,816&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zrB2JGwUYSye" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z3APahcsFgU1" title="Property and equipment, estimated useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zxmRKKC9Tds9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zsWPqsOKmF86" title="Property and equipment, estimated useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,898&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zbQMqJY34k6h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z0Eece87vQx7" title="Property and equipment, estimated useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;474,462&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;471,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ConstructionInProgressEquipmentMember_z7qpdWZuBNfj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Construction-in-process- equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;375,278&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;207,976&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzeQW_zjxFuMf7cDIi" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,400,749&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,188,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzeQW_zs4CDjS0ABh5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,296,074&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,642,984&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzeQW_zG2UZQJQb5d8" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,104,675&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,545,965&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_EquipmentMember_srt_MinimumMember"
      id="Fact000615">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_EquipmentMember_srt_MaximumMember"
      id="Fact000617">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_EquipmentMember"
      decimals="0"
      id="Fact000612"
      unitRef="USD">4358261</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_EquipmentMember"
      decimals="0"
      id="Fact000613"
      unitRef="USD">4321816</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      id="Fact000622">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000619"
      unitRef="USD">145754</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000620"
      unitRef="USD">145754</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember"
      id="Fact000627">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact000624"
      unitRef="USD">46994</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact000625"
      unitRef="USD">41898</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      id="Fact000632">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000629"
      unitRef="USD">474462</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000630"
      unitRef="USD">471505</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_ConstructionInProgressEquipmentMember"
      decimals="0"
      id="Fact000634"
      unitRef="USD">375278</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ConstructionInProgressEquipmentMember"
      decimals="0"
      id="Fact000635"
      unitRef="USD">207976</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000637"
      unitRef="USD">5400749</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000638"
      unitRef="USD">5188949</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000640"
      unitRef="USD">3296074</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000641"
      unitRef="USD">2642984</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000643"
      unitRef="USD">2104675</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000644"
      unitRef="USD">2545965</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000646"
      unitRef="USD">653090</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000648"
      unitRef="USD">582918</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000650">&lt;p id="xdx_806_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zFX1Y4wYRkph" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(5)
&lt;span id="xdx_82A_zIgUaVrSxZMf"&gt;Accrued Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zX5147gosxsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
expenses consisted of the following at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_z6fObRRUxEK5" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zNOVqq171VBf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231_ze1KLBeAmOKd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--WorkersCompensationLiabilityCurrent_iI_maALCzF0a_zREutEDK5GVk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;355,475&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;593,022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedResearchAndDevelopmentCostsCurrent_iI_maALCzF0a_zW5RWF91yho7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;341,956&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;155,220&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_maALCzF0a_z5Jcnvplp33e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State franchise taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;120,570&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzF0a_zRsxnxgBsTaf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;56,476&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66,897&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedInsuranceCurrent_iI_maALCzF0a_z0GfWN26WBY" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,469&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;56,088&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedUtilitiesCurrent_iI_maALCzF0a_zUO0axFXILo1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;CIP- Equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,160&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;155,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--InterestPayableCurrent_iI_maALCzF0a_zr8s9ktXDUMe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,089&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;290,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzF0a_zG4xBZh6r4dk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;213,922&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzF0a_z7de5KtImXbg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,039,625&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,651,519&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zLwFwVNNHAl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000652">&lt;p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zX5147gosxsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
expenses consisted of the following at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_z6fObRRUxEK5" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zNOVqq171VBf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231_ze1KLBeAmOKd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--WorkersCompensationLiabilityCurrent_iI_maALCzF0a_zREutEDK5GVk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;355,475&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;593,022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedResearchAndDevelopmentCostsCurrent_iI_maALCzF0a_zW5RWF91yho7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;341,956&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;155,220&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_maALCzF0a_z5Jcnvplp33e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State franchise taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;120,570&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzF0a_zRsxnxgBsTaf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;56,476&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66,897&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedInsuranceCurrent_iI_maALCzF0a_z0GfWN26WBY" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,469&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;56,088&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedUtilitiesCurrent_iI_maALCzF0a_zUO0axFXILo1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;CIP- Equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,160&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;155,800&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--InterestPayableCurrent_iI_maALCzF0a_zr8s9ktXDUMe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,089&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;290,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzF0a_zG4xBZh6r4dk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;213,922&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzF0a_z7de5KtImXbg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,039,625&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,651,519&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000654"
      unitRef="USD">355475</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000655"
      unitRef="USD">593022</us-gaap:WorkersCompensationLiabilityCurrent>
    <CING:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000657"
      unitRef="USD">341956</CING:AccruedResearchAndDevelopmentCostsCurrent>
    <CING:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000658"
      unitRef="USD">155220</CING:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000660"
      unitRef="USD">200000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000661"
      unitRef="USD">120570</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000663"
      unitRef="USD">56476</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000664"
      unitRef="USD">66897</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000666"
      unitRef="USD">34469</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000667"
      unitRef="USD">56088</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedUtilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000669"
      unitRef="USD">31160</us-gaap:AccruedUtilitiesCurrent>
    <us-gaap:AccruedUtilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000670"
      unitRef="USD">155800</us-gaap:AccruedUtilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000672"
      unitRef="USD">15089</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000673"
      unitRef="USD">290000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000675"
      unitRef="USD">5000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000676"
      unitRef="USD">213922</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000678"
      unitRef="USD">1039625</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000679"
      unitRef="USD">1651519</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LossContingencyDisclosures contextRef="From2024-01-01to2024-12-31" id="Fact000681">&lt;p id="xdx_80A_eus-gaap--LossContingencyDisclosures_zCuGoxXwjqY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(6)
&lt;span id="xdx_82C_zUbU18VNcoGe"&gt;Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company may, from time to time, be subject to legal proceedings and claims arising in the ordinary course of business and otherwise.
A substantial legal liability against us could have an adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company records legal costs associated with loss contingencies as incurred and establishes reserves when those matters present material
loss contingencies that management determines to be both probable and reasonably estimable in accordance with ASC Topic 450, &lt;i&gt;Contingencies.
&lt;/i&gt;If a range of loss is estimated, and some amount within that range appears to be a better estimate than any other amount within that
range, then that amount is accrued. If no amount within the range can be identified as a better estimate than any other amount, we accrue
the minimum amount in the range. These amounts are not reduced by amounts that may be recovered under insurance or claims against third
parties, but undiscounted receivables from insurers or other third parties may be accrued separately if recovery is considered probable.
Management&#x2019;s judgment is required related to loss contingencies because the outcomes are difficult to predict, and the ultimate
resolution may differ from our current analysis. The Company revises accruals in light of new information. While it is not possible to
predict the outcome of loss contingencies with certainty, management is of the opinion that adequate provision for potential losses associated
with any such matters has been made in the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, the Company implemented salary
reductions for all employees and the Board approved a contingent bonus plan in which the Company will pay to each employee three
months after the filing date of the New Drug Application for CTx-1301, an amount equal to the base salary that was not paid to the
employee plus 20%. Base salaries were reinstated in September 2024. While this contingent bonus has not yet been deemed probable per the requirements of ASC Topic 450, &lt;i&gt;Contingencies&lt;/i&gt;,
thus not recorded in the financial statements, it is reasonably possible that it will become due. The unpaid salary amounts plus
20%, estimated to be $&lt;span id="xdx_905_eus-gaap--SalariesWagesAndOfficersCompensation_c20230101__20231231_zWatRdVjCoda" title="Unpaid salary"&gt;722,824&lt;/span&gt;,
may be paid in a combination of cash and equity awards, at the discretion of the Board.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LossContingencyDisclosures>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000683"
      unitRef="USD">722824</us-gaap:SalariesWagesAndOfficersCompensation>
    <CING:RelatedPartyNotePaybleDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000685">&lt;p id="xdx_803_ecustom--RelatedPartyNotePaybleDisclosureTextBlock_zvXgS5W5yoO7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(7) &lt;span id="xdx_82A_z4poUJwS71B7"&gt;Related
Party Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
August 2022, the Company received $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20220801__20220831__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_z0BcgFk1Ny6h" title="Issuance of debt"&gt;5.0&lt;/span&gt; million of debt financing from Werth Family Investment Associates LLC (WFIA). Peter Werth, manager
of WFIA, is a member of the Company&#x2019;s Board of Directors. The promissory note, dated August 9, 2022, was unsecured with interest
accruing at &lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220809__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zDjTHGw0jXdi" title="Unsecured interest percentage"&gt;15&lt;/span&gt;% per annum. In May 2023, the Company received an additional $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_pn5n6_c20230501__20230531_zQLbanAFT8Lb" title="Issuance of long term debt"&gt;3.0&lt;/span&gt; million of debt financing from WFIA by amending and restating
the note to increase the principal amount to $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230531_z5BHBeHD5uP2" title="Debt face amount"&gt;8.0&lt;/span&gt; million. All other terms of the note remained the same.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 8, 2023, the Company and CTx entered into a note conversion agreement with WFIA, pursuant to which WFIA agreed to convert the
original principal amount of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230908__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zqdtnRyVn5Kc" title="Debt face amount"&gt;5.0&lt;/span&gt; million under the note plus all accrued interest on the original principal, or $&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstanding_iI_c20230908__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zerqdiTrH5j4" title="Issuance date fair value total"&gt;5,812,500&lt;/span&gt;, by issuing
pre-funded warrants to purchase &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230908__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_z1sMq5hP0br6" title="Number of warrants"&gt;28,493&lt;/span&gt; shares of the Company&#x2019;s common stock at a conversion price per pre-funded warrant of $&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20230908__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zzIGaeOwzVcd" title="Issuance date fair value per warrant"&gt;204.00&lt;/span&gt;.
The closing price of the Company&#x2019;s common stock on Nasdaq on September 8, 2023, was $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230908__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zUeOaudJWVP1" title="Exercise price"&gt;13.56&lt;/span&gt; per share. &lt;span id="xdx_904_eus-gaap--DebtInstrumentDescription_c20230908__20230908__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zij0Tivl9Mv6" title="Debt instrument, description"&gt;The pre-funded warrants had
no expiration date and were exercisable immediately at an exercise price of $&lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_iI_pid_c20230908__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_za3ZlMcRR65e" title="Debt instrument, description"&gt;0.024&lt;/span&gt; per share, to the extent that after giving effect
to such exercise, WFIA and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934,
as amended (Exchange Act), no more than 19.99% of the outstanding shares of common stock of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
January 25, 2024, the Company and CTx entered into another note conversion agreement with WFIA, pursuant to which WFIA agreed to convert
the remaining principal amount of the note payable of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240125__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_z43E2eiWv8Fa"&gt;3.0&lt;/span&gt; million plus all accrued interest, or $&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstanding_iI_c20240125__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_z7u3q28VKlL"&gt;3,287,500&lt;/span&gt;, by issuing pre-funded warrants
to purchase &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240125__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_z1oeO5UjUNFc"&gt;57,254&lt;/span&gt; shares of the Company&#x2019;s common stock at a conversion price per pre-funded warrant of $&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20240125__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_z6m0gxNYV735" title="Issuance date fair value per warrant"&gt;57.42&lt;/span&gt;. The closing price
of the Company&#x2019;s common stock on Nasdaq on January 24, 2024, was $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240125__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zvS84HDbcyR9"&gt;52.20&lt;/span&gt; per share. &lt;span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20240125__20240125__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zdW2BUykCudd"&gt;The pre-funded warrants had no expiration date
and were exercisable immediately at an exercise price of $&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_iI_pid_c20240125__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zxXW5Eu7wPJ9" title="Warrants, excercise price"&gt;0.0012&lt;/span&gt; per share, to the extent that after giving effect to such exercise,
WFIA and its affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding
shares of common stock of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;WFIA
exercised all of its pre-funded warrants in April 2024, as described in Note 10.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company considered ASC 470-60, &lt;i&gt;Troubled Debt Restructurings by Debtors&lt;/i&gt;, in accounting for the debt conversions. Due to the related
party nature of the transactions, the difference between the fair value of the pre-funded warrants issued and the carrying value of the
debt settled in the transactions were recognized as capital contributions in the Statement of Stockholders&#x2019; Equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</CING:RelatedPartyNotePaybleDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2022-08-012022-08-31_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="-5"
      id="Fact000687"
      unitRef="USD">5000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-08-09_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="INF"
      id="Fact000689"
      unitRef="Pure">0.15</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="From2023-05-012023-05-31"
      decimals="-5"
      id="Fact000691"
      unitRef="USD">3000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-05-31"
      decimals="-5"
      id="Fact000693"
      unitRef="USD">8000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-09-08_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="-5"
      id="Fact000695"
      unitRef="USD">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-09-08_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="0"
      id="Fact000697"
      unitRef="USD">5812500</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-08_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="INF"
      id="Fact000699"
      unitRef="Shares">28493</us-gaap:ClassOfWarrantOrRightOutstanding>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2023-09-08_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="INF"
      id="Fact000701"
      unitRef="USDPShares">204.00</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-08_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="INF"
      id="Fact000703"
      unitRef="USDPShares">13.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2023-09-082023-09-08_custom_WerthFamilyInvestmentAssociatesLLCMember"
      id="Fact000705">The pre-funded warrants had
no expiration date and were exercisable immediately at an exercise price of $0.024 per share, to the extent that after giving effect
to such exercise, WFIA and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934,
as amended (Exchange Act), no more than 19.99% of the outstanding shares of common stock of the Company.</us-gaap:DebtInstrumentDescription>
    <CING:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="AsOf2023-09-08_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="INF"
      id="Fact000707"
      unitRef="USDPShares">0.024</CING:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-25_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="-5"
      id="Fact000708"
      unitRef="USD">3000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-01-25_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="0"
      id="Fact000709"
      unitRef="USD">3287500</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-01-25_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="INF"
      id="Fact000710"
      unitRef="Shares">57254</us-gaap:ClassOfWarrantOrRightOutstanding>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2024-01-25_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="INF"
      id="Fact000712"
      unitRef="USDPShares">57.42</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-25_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="INF"
      id="Fact000713"
      unitRef="USDPShares">52.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2024-01-252024-01-25_custom_WerthFamilyInvestmentAssociatesLLCMember"
      id="Fact000714">The pre-funded warrants had no expiration date
and were exercisable immediately at an exercise price of $0.0012 per share, to the extent that after giving effect to such exercise,
WFIA and its affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding
shares of common stock of the Company.</us-gaap:DebtInstrumentDescription>
    <CING:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="AsOf2024-01-25_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="INF"
      id="Fact000716"
      unitRef="USDPShares">0.0012</CING:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000718">&lt;p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zzQDKyVsBnX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(8)
&lt;span id="xdx_824_zaxXfjqaFR44"&gt;Unsecured Promissory Note&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
December 20, 2024, the Company entered into a note purchase agreement with Streeterville Capital, LLC, a Utah limited liability company
(Lender), pursuant to which the Company issued and sold to Lender an unsecured promissory note (Promissory Note) in the amount of $&lt;span id="xdx_903_eus-gaap--UnsecuredLongTermDebt_iI_c20241220__dei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember_zAlwa3PsHrok" title="Unsecured promissory note amount"&gt;5,480,000&lt;/span&gt;.
The Promissory Note included an original issue discount of $&lt;span id="xdx_903_ecustom--DebtInstrumentOriginalDiscount_iI_c20241220__dei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember_zzn40ctKTBjh" title="Unsecured promissory note original discount"&gt;450,000&lt;/span&gt; and Lender expenses payable by the Company of $&lt;span id="xdx_904_ecustom--LenderExpensesOnIssueOfDebt_iI_c20241220__dei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember_zuROFiSc3AU1" title="Lender expenses on issue of debt"&gt;30,000&lt;/span&gt;. In exchange
for the Promissory Note, the Lender paid a purchase price of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20241220__dei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember_zoh9eG3SWVMj" title="Proceeds from issuance of promissory note"&gt;5,000,000&lt;/span&gt; in cash. The Promissory Note bears interest at a rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241220__dei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember_zpZkg3TP9xH8" title="Interest rate percent"&gt;9&lt;/span&gt;% per
annum and matures 18 months after its issuance date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;From
time to time, beginning on July 2, 2025, Lender may redeem a portion of the Promissory Note, not to exceed an amount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_c20250702__20250702__dei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zZnAP7EMSged" title="Redemption of promissory note"&gt;550,000&lt;/span&gt; per
month. &lt;span id="xdx_90D_eus-gaap--DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_c20250702__20250702__dei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z54AXDGUBdyj" title="Description of monitoring fee in event of default"&gt;In the event the Promissory Note is outstanding on the 90-day anniversary of the effective date of the Promissory Note, the Company
will be charged and record a monitoring fee equal to the outstanding principal balance on such date divided by 0.85 less the outstanding
balance on such date. The monitoring fee and interest accrued on the monitoring fee will be forgiven, on a pro rata basis, each time
the Company makes a cash payment on the Promissory Note. Subject to the terms and conditions set forth in the Promissory Note, the Company
may prepay all or any portion of the outstanding balance of the Promissory Note at any time.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Promissory Note provides for customary events of default (each, an Event of Default), including, among other things, the event of nonpayment
of principal, interest, fees or other amounts, a representation or warranty proving to have been incorrect when made, failure to perform
or observe covenants within a specified cure period, a cross-default to certain other indebtedness and material agreements of the Company,
and the occurrence of a bankruptcy, insolvency or similar event affecting the Company. &lt;span id="xdx_90A_ecustom--DefaultLongtermDebtDescriptionOfEventOfDefault_c20241220__20241220_zv6FqSFME2Xb" title="Description of monitoring fee in event of default"&gt;Upon the occurrence of an Event of Default that
is deemed a &#x201c;Major Trigger Event&#x201d; as defined in the Promissory Note, Lender may increase the outstanding balance of the Promissory
Note by 15%, and upon the occurrence of an Event of Default that is deemed a &#x201c;Minor Trigger Event&#x201d; as defined in the Promissory
Note, Lender may increase the outstanding balance of the Promissory Note by 5%. Lender can exercise its right to increase the outstanding
balance upon a Major or Minor Trigger Event three times each. Upon the occurrence of an Event of Default, Lender may declare all amounts
owed under the Promissory Note immediately due and payable. In addition, upon the occurrence of an Event of Default, upon the election
of Lender, interest shall begin accruing on the outstanding balance of the Promissory Note from the date of the Event of Default equal
to the lesser of 22% per annum and the maximum rate allowable under law.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
connection with the Promissory Note, the Company incurred $&lt;span id="xdx_90D_eus-gaap--PaymentsOfDebtIssuanceCosts_c20241220__20241220__dei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember_z0rC6dAF2pj9" title="Debt issuance costs"&gt;46,277&lt;/span&gt; of debt issuance costs. The debt issuance costs, the debt discount
of $&lt;span id="xdx_903_ecustom--DebtInstrumentOriginalDiscount_iI_c20241220__dei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember_zwogZcEh9Bic" title="Unsecured promissory note original discount"&gt;450,000&lt;/span&gt; and the expenses payable by the Company of $&lt;span id="xdx_904_ecustom--LenderExpensesOnIssueOfDebt_iI_c20241220__dei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember_z5txRMnmq2h" title="Lender expenses on issue of debt"&gt;30,000&lt;/span&gt; have been recorded as a reduction in the carrying amount of the Promissory
Note and are being amortized over the term of the Promissory Note using the effective interest rate method. As of December 31, 2024,
the collective amount of unamortized debt discount and debt issuance costs were $&lt;span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20241231__dei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember_zyDUNDDa3EC4" title="Unsecured promissory note discount"&gt;516,012&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2024, the outstanding principal balance of the Promissory Note plus accrued interest was $&lt;span id="xdx_907_ecustom--LongtermDebtOutstandingIncludingAccruedInterest_iI_c20241231__dei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember_z6ZmJlw8kl4c" title="Long-term debt outstanding including accrued interest"&gt;5,495,089&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--InterestIncomeAndInterestExpenseDisclosureTableTextBlock_z88udQGOuEW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table provides a breakdown of interest expense (income) for the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B6_zO0qaNYXGZ5"&gt;Schedule
of Interest Expense (Income) &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20240101__20241231_zME9qCyDQkq8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20230101__20231231_zO3IieHDTEmg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherNonoperatingExpense_hdei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zW8IM0cCOJz5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Interest expense - WFIA&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;31,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;810,162&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherNonoperatingExpense_hdei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember_zSozWzniYS1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest expense - Streeterville Capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0752"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OtherNonoperatingExpense_hdei--LegalEntityAxis__custom--OtherMember_zSdeQ1QPGkdc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense - other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherNonoperatingIncome_iN_di_zvelpr0z24R" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Interest income&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(162,099&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(53,825&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_iNT_di_zJ2pW8jx5Hg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(99,236&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;775,758&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AC_zg86TWEJ8yL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:UnsecuredLongTermDebt
      contextRef="AsOf2024-12-20_custom_StreetvilleCapitalLLCMember"
      decimals="0"
      id="Fact000720"
      unitRef="USD">5480000</us-gaap:UnsecuredLongTermDebt>
    <CING:DebtInstrumentOriginalDiscount
      contextRef="AsOf2024-12-20_custom_StreetvilleCapitalLLCMember"
      decimals="0"
      id="Fact000722"
      unitRef="USD">450000</CING:DebtInstrumentOriginalDiscount>
    <CING:LenderExpensesOnIssueOfDebt
      contextRef="AsOf2024-12-20_custom_StreetvilleCapitalLLCMember"
      decimals="0"
      id="Fact000724"
      unitRef="USD">30000</CING:LenderExpensesOnIssueOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-20_custom_StreetvilleCapitalLLCMember"
      decimals="0"
      id="Fact000726"
      unitRef="USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-12-20_custom_StreetvilleCapitalLLCMember"
      decimals="INF"
      id="Fact000728"
      unitRef="Pure">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2025-07-022025-07-02_custom_StreetvilleCapitalLLCMember_srt_ScenarioForecastMember"
      decimals="0"
      id="Fact000730"
      unitRef="USD">550000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault
      contextRef="From2025-07-022025-07-02_custom_StreetvilleCapitalLLCMember_srt_ScenarioForecastMember"
      id="Fact000732">In the event the Promissory Note is outstanding on the 90-day anniversary of the effective date of the Promissory Note, the Company
will be charged and record a monitoring fee equal to the outstanding principal balance on such date divided by 0.85 less the outstanding
balance on such date. The monitoring fee and interest accrued on the monitoring fee will be forgiven, on a pro rata basis, each time
the Company makes a cash payment on the Promissory Note. Subject to the terms and conditions set forth in the Promissory Note, the Company
may prepay all or any portion of the outstanding balance of the Promissory Note at any time.</us-gaap:DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault>
    <CING:DefaultLongtermDebtDescriptionOfEventOfDefault contextRef="From2024-12-202024-12-20" id="Fact000734">Upon the occurrence of an Event of Default that
is deemed a &#x201c;Major Trigger Event&#x201d; as defined in the Promissory Note, Lender may increase the outstanding balance of the Promissory
Note by 15%, and upon the occurrence of an Event of Default that is deemed a &#x201c;Minor Trigger Event&#x201d; as defined in the Promissory
Note, Lender may increase the outstanding balance of the Promissory Note by 5%. Lender can exercise its right to increase the outstanding
balance upon a Major or Minor Trigger Event three times each. Upon the occurrence of an Event of Default, Lender may declare all amounts
owed under the Promissory Note immediately due and payable. In addition, upon the occurrence of an Event of Default, upon the election
of Lender, interest shall begin accruing on the outstanding balance of the Promissory Note from the date of the Event of Default equal
to the lesser of 22% per annum and the maximum rate allowable under law.</CING:DefaultLongtermDebtDescriptionOfEventOfDefault>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-12-202024-12-20_custom_StreetvilleCapitalLLCMember"
      decimals="0"
      id="Fact000736"
      unitRef="USD">46277</us-gaap:PaymentsOfDebtIssuanceCosts>
    <CING:DebtInstrumentOriginalDiscount
      contextRef="AsOf2024-12-20_custom_StreetvilleCapitalLLCMember"
      decimals="0"
      id="Fact000738"
      unitRef="USD">450000</CING:DebtInstrumentOriginalDiscount>
    <CING:LenderExpensesOnIssueOfDebt
      contextRef="AsOf2024-12-20_custom_StreetvilleCapitalLLCMember"
      decimals="0"
      id="Fact000740"
      unitRef="USD">30000</CING:LenderExpensesOnIssueOfDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-12-31_custom_StreetvilleCapitalLLCMember"
      decimals="0"
      id="Fact000742"
      unitRef="USD">516012</us-gaap:DebtInstrumentUnamortizedDiscount>
    <CING:LongtermDebtOutstandingIncludingAccruedInterest
      contextRef="AsOf2024-12-31_custom_StreetvilleCapitalLLCMember"
      decimals="0"
      id="Fact000744"
      unitRef="USD">5495089</CING:LongtermDebtOutstandingIncludingAccruedInterest>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000746">&lt;p id="xdx_896_eus-gaap--InterestIncomeAndInterestExpenseDisclosureTableTextBlock_z88udQGOuEW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table provides a breakdown of interest expense (income) for the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B6_zO0qaNYXGZ5"&gt;Schedule
of Interest Expense (Income) &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20240101__20241231_zME9qCyDQkq8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20230101__20231231_zO3IieHDTEmg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherNonoperatingExpense_hdei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zW8IM0cCOJz5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Interest expense - WFIA&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;31,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;810,162&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherNonoperatingExpense_hdei--LegalEntityAxis__custom--StreetvilleCapitalLLCMember_zSozWzniYS1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest expense - Streeterville Capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0752"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OtherNonoperatingExpense_hdei--LegalEntityAxis__custom--OtherMember_zSdeQ1QPGkdc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense - other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherNonoperatingIncome_iN_di_zvelpr0z24R" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Interest income&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(162,099&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(53,825&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_iNT_di_zJ2pW8jx5Hg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(99,236&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;775,758&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-01-012024-12-31_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="0"
      id="Fact000748"
      unitRef="USD">31250</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-01-012023-12-31_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="0"
      id="Fact000749"
      unitRef="USD">810162</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-01-012024-12-31_custom_StreetvilleCapitalLLCMember"
      decimals="0"
      id="Fact000751"
      unitRef="USD">25354</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-01-012024-12-31_custom_OtherMember16236156"
      decimals="0"
      id="Fact000754"
      unitRef="USD">6259</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-01-012023-12-31_custom_OtherMember16236156"
      decimals="0"
      id="Fact000755"
      unitRef="USD">19421</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000757"
      unitRef="USD">162099</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000758"
      unitRef="USD">53825</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000760"
      unitRef="USD">99236</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000761"
      unitRef="USD">-775758</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000763">&lt;p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zjUmljZxIWDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(9)
&lt;span id="xdx_827_zwdl9vfuluce"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has authorized &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zDr4I334yYtc" title="Common stock shares authorized"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zLXkdx8gSwni" title="Common stock shares authorized"&gt;240,000,000&lt;/span&gt;&lt;/span&gt; shares of $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zRfanyCJAhBk" title="Common stock par value"&gt;&lt;span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_z9me8d14K3e5" title="Common stock par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt; par value common stock and &lt;span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zFkhZPE57ozf" title="Preferred stock shares authorized"&gt;&lt;span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zVa9XpjVgep1" title="Preferred stock shares authorized"&gt;10,000,000&lt;/span&gt;&lt;/span&gt; shares of $&lt;span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_zW4ZNZ4RdUui" title="Preferred stock par value"&gt;&lt;span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_za89DuKah9Ed" title="Preferred stock par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt; par value preferred stock
at December 31, 2024 and 2023 of which &lt;span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20241231_z5rkjRif4t7" title="Common stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z2itzEVzOj81" title="Common stock, shares outstanding"&gt;3,402,306&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20231231_z8HTzHdGfCq8" title="Common stock, shares issued"&gt;&lt;span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_z2RFJiQGlVCl" title="Common stock, shares outstanding"&gt;97,293&lt;/span&gt;&lt;/span&gt; shares of common stock were issued and outstanding, respectively. The Company
has not issued any shares of preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
holders of common stock are entitled to one vote for each share of common stock. In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the
holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution, if any. Holders
of the shares of common stock are entitled to dividends when, as and if declared by the Board of Directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Reverse
Stock Splits&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
November 30, 2023, the Company completed a &lt;span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20231130__20231130_zPzWwLxyw5t6" title="Stockholders equity, reverse stock split"&gt;one-for-twenty&lt;/span&gt; reverse stock split (2023 Reverse Stock Split), which reduced the number of
shares of the Company&#x2019;s common stock that were issued and outstanding immediately prior to the effectiveness of the 2023 Reverse
Stock Split. The number of shares of the Company&#x2019;s authorized common stock was not affected by the 2023 Reverse Stock Split and
the par value of the Company&#x2019;s common stock remained unchanged at $&lt;span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231130_zvDQtw0cQnpc"&gt;0.0001&lt;/span&gt; per share. No fractional shares were issued in connection
with the 2023 Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
August 9, 2024, the Company completed a &lt;span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20240809__20240809_zkTf7hUOIGga" title="Stockholders equity, reverse stock split"&gt;one-for-twelve reverse stock split&lt;/span&gt; (2024 Reverse Stock Split), which reduced the number of shares
of the Company&#x2019;s common stock that were issued and outstanding immediately prior to the effectiveness of the 2024 Reverse Stock
Split. The number of shares of the Company&#x2019;s authorized common stock was not affected by the 2024 Reverse Stock Split and the par
value of the Company&#x2019;s common stock remained unchanged at $&lt;span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240809_zB327vNuOd7f"&gt;0.0001&lt;/span&gt; per share. No fractional shares were issued in connection with
the 2024 Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Except
where disclosed, all amounts related to number of shares and per share amounts have been retrospectively restated in these financial
statements to reflect the 2023 Reverse Stock Split and the 2024 Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000765"
      unitRef="Shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000767"
      unitRef="Shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000769"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000771"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000773"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000775"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000777"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000779"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000781"
      unitRef="Shares">3402306</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000783"
      unitRef="Shares">3402306</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000785"
      unitRef="Shares">97293</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000787"
      unitRef="Shares">97293</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-11-302023-11-30" id="Fact000789">one-for-twenty</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-11-30"
      decimals="INF"
      id="Fact000790"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-08-092024-08-09" id="Fact000792">one-for-twelve reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-08-09"
      decimals="INF"
      id="Fact000793"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <CING:SaleOfCommonStockTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000795">&lt;p id="xdx_802_ecustom--SaleOfCommonStockTextBlock_z9DmT3Qun5K5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(10)
&lt;span id="xdx_822_zYYChVJ52Fk6"&gt;Securities Issuances&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Private
Placement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
August 11, 2023, the Company entered into a securities purchase agreement with WFIA and issued, in a private placement priced at the
market under Nasdaq rules, &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230811__20230811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ9LHY2gqMFl" title="New shares , issued"&gt;7,597&lt;/span&gt; shares of its common stock at a purchase price per share of $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_c20230811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHDEwqKntoMf" title="Share price"&gt;131.64&lt;/span&gt;, resulting in gross proceeds to
the Company of approximately $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230811__20230811__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNLTZ4fywe5e" title="Gross proceeds"&gt;1.0&lt;/span&gt; million. Peter Werth, a member of the Company&#x2019;s Board of Directors, is the manager of WFIA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Public
Offerings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 11, 2023, the Company entered into a securities purchase agreement with an institutional investor (September 2023 Offering)
pursuant to which the Company issued &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230911__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAandSeriesBWarrantsMember_zqg7hsa1kLYk" title="Number of warrants"&gt;7,167&lt;/span&gt; shares of its common stock at a combined price of $&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20230911__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAandSeriesBWarrantsMember_zkxeqrE6R1lk" title="Issuance date fair value per warrant"&gt;138.62&lt;/span&gt; per share and accompanying Series
A and Series B warrants, and pre-funded warrants to purchase up to an aggregate of &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230911__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z6XyeaQLZbLe" title="Number of warrants"&gt;21,688&lt;/span&gt; shares of its common stock at a combined purchase
price of $&lt;span id="xdx_90E_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20230911__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zhJXiBHHlTQ2" title="Issuance date fair value per warrant"&gt;138.62&lt;/span&gt; per pre-funded warrant and accompanying Series A and Series B warrants, which represents the public offering price for
the common stock less the $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230911__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zkzSjrvRRrga" title="Warrant exercise price"&gt;0.024&lt;/span&gt; per share exercise price per share for each pre-funded warrant. &lt;span id="xdx_90D_eus-gaap--DebtInstrumentDescription_c20230911__20230911_z89Ms5Q4DdIh" title="Debt descripition"&gt;The September 2023 Offering closed on
September 13, 2023. The pre-funded warrants were exercisable at any time after the date of issuance and had no expiration date. The holders
of pre-funded warrants could not exercise the warrants if the holder, together with its affiliates, would beneficially own more than
4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect
to such exercise.&lt;/span&gt; The September 2023 Offering resulted in gross proceeds to the Company of $&lt;span id="xdx_909_ecustom--GrossProceeds_c20230911__20230911_zYlVcBHw3uAg" title="Gross proceeds"&gt;3,999,480&lt;/span&gt; before deducting $&lt;span id="xdx_909_eus-gaap--PaymentsForFees_c20230911__20230911_zrqdwT1DZ9Ui" title="Placement agent fees"&gt;688,929&lt;/span&gt; of placement
agent fees and other offering expenses. See Note 11 for a description of Series A and Series B warrants issued in the September 2023
Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
February 2, 2024, the Company completed a public offering (February 2024 Offering) pursuant to which the Company issued &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240202__us-gaap--StatementClassOfStockAxis__custom--SeriesAandSeriesBWarrantsMember_zjZwrd6Nqtod"&gt;114,583&lt;/span&gt; shares
of its common stock and accompanying Series A and Series B warrants at a combined price of $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20240202__us-gaap--StatementClassOfStockAxis__custom--SeriesAandSeriesBWarrantsMember_zlRpL0UHh6o9"&gt;24.00&lt;/span&gt; per share, and pre-funded warrants
to purchase up to an aggregate of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAandSeriesBWarrantsMember_zKpctMHi5FRf"&gt;197,917&lt;/span&gt; shares of its common stock and accompanying Series A and Series B warrants at a combined purchase
price of $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAandSeriesBWarrantsMember_z75eCyZnAail"&gt;23.988&lt;/span&gt; per pre-funded warrant, which represents the public offering price for the common stock less the $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAandSeriesBWarrantsMember_z8OmMurBIZ02"&gt;0.0012&lt;/span&gt; per share exercise
price per share for each pre-funded warrant. The pre-funded warrants were exercisable at any time after the date of issuance and had
no expiration date. &lt;span id="xdx_901_eus-gaap--DebtInstrumentDescription_c20240202__20240202_zVjw3GD4cij1"&gt;The holders of pre-funded warrants could not exercise the warrants if the holder, together with its affiliates, would
beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately
after giving effect to such exercise. Each share of common stock and each pre-funded warrant were sold along with one Series A and 0.5
Series B warrants.&lt;/span&gt; The February 2024 Offering resulted in gross proceeds to the Company of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20240202__20240202_z75z9cbNEFXc"&gt;7.5&lt;/span&gt; million before deducting $&lt;span id="xdx_901_eus-gaap--PaymentsForFees_c20240202__20240202_z0awhFACcSIg"&gt;750,950&lt;/span&gt; of
placement agent fees and other offering expenses. As of December 31, 2024, all of the pre-funded warrants issued in the February 2024
Offering had been exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Conversion
of Related Party Note&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 8, 2023, the Company issued to WFIA pre-funded warrants to purchase &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230908__us-gaap--ClassOfWarrantOrRightAxis__custom--WFIAPreFundedWarrantsMember_z2dULBmgrSga" title="Number of warrants"&gt;28,493&lt;/span&gt; shares of the Company&#x2019;s common stock as part
of a note conversion agreement, as described in Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
January 25, 2024, the Company issued to WFIA pre-funded warrants to purchase &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240125__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zeDSvtuuFeo"&gt;57,254&lt;/span&gt; shares of the Company&#x2019;s common stock as part
of a note conversion agreement, as described in Note 7. In March 2024, the Company issued to WFIA additional pre-funded warrants to purchase
&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240331__dei--LegalEntityAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zlXRpwk6Td46" title="Prefunded warrants"&gt;588&lt;/span&gt; shares of the Company&#x2019;s common stock as a result of an error in the interest calculation, on the same form and at the same
conversion price as the pre-funded warrants issued in January 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
April 2024, WFIA exercised all of its pre-funded warrants, as described in Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Warrant
Inducement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
June 28, 2024, the Company entered into an inducement offer letter agreement (June 2024 Warrant Inducement), in which certain holders
(Holders) of certain of its existing warrants to purchase &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240628__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwentyTwentyFourWarrantsInducementMember_z1zCVpGCvHcc" title="Existing warrants to purchase"&gt;265,625&lt;/span&gt; shares of the Company&#x2019;s common stock issued to the Holders in
connection with the February 2024 Offering (February 2024 Warrants) agreed to exercise for cash their February 2024 Warrants at a reduced
exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240628__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyFourWarrantsMember_zdfvLJMDnhM7"&gt;7.02&lt;/span&gt; per share. In consideration for the exercise of the February 2024 Warrants, the Holders received, in addition
to the reduced exercise price, new Series C common stock purchase warrants to purchase an aggregate of &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240628__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--CommonClassCMember_z1c5qFiMQ6dg"&gt;354,167&lt;/span&gt; shares of the Company&#x2019;s
common stock and new Series D common stock purchase warrants to purchase an aggregate of &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240628__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDCommonStockMember_zRAj2Kb09U8i"&gt;177,083&lt;/span&gt; shares of the Company&#x2019;s common
stock. The June 2024 Warrant Inducement is considered a modification of the existing warrants under ASC Subtopic 815-40, &lt;i&gt;Derivatives
and Hedging, Contracts in Entity&#x2019;s Own Equity&lt;/i&gt;. This modification is consistent with the equity issuance classification under
ASC Subtopic 815-40 as the reason for the modification was to induce the holders of the existing warrants to exercise their warrants,
which raised equity capital and generated net proceeds to the Company of approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwentyTwentyFourWarrantsInducementMember_zOLNr4HhTMhj"&gt;1.6&lt;/span&gt; million, after deducting the placement agent
fees and other offering expenses payable by the Company. The modified warrants were classified as equity instruments before and after
the modification, and the modification is directly attributable to an equity offering. The Company recognized the effect of modification
of approximately $&lt;span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwentyTwentyFourWarrantsInducementMember_z7JKTjLDGgh" title="Payments of stock issuance costs"&gt;2.0&lt;/span&gt; million as an equity issuance cost and accounting effect of the inducement is recognized in the Statement of Stockholders&#x2019;
Equity. The Company received net proceeds of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwentyTwentyFourWarrantsInducementMember_z0TjZPy1f5p9" title="Proceeds from issuance or sale of equity"&gt;1.6&lt;/span&gt; million on the closing of the June 2024 Warrant Inducement, which occurred on July
1, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Purchase
Agreement with Lincoln Park&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
April 2023, the Company entered into a purchase agreement (LP Purchase Agreement) and a registration rights agreement (Registration Rights
Agreement) with Lincoln Park Capital Fund, LLC (Lincoln Park). Pursuant to the terms of the LP Purchase Agreement, Lincoln Park has agreed
to purchase from the Company up to $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20230401__20230430__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zLHEHqIDkhpi" title="Proceeds from issuance of common stock"&gt;12&lt;/span&gt; million of the Company&#x2019;s common stock subject to certain limitations and satisfaction of
the conditions set forth in the LP Purchase Agreement. Pursuant to the terms of the Registration Rights Agreement, the Company filed
with the SEC registration statements to register for resale under the Securities Act &lt;span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zHY4tbh8kIc9" title="Sale of stock"&gt;2,685,417&lt;/span&gt; shares of common stock that have been
or may be issued to Lincoln Park under the LP Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to the terms of the LP Purchase Agreement, at the time the Company signed the LP Purchase Agreement and the Registration Rights Agreement,
the Company issued &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zeP1OHcwU0og" title="Number of shares issued, shares"&gt;1,534&lt;/span&gt; shares of common stock to Lincoln Park as consideration for its commitment to purchase shares of common stock
under the LP Purchase Agreement. The commitment shares were valued at $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zwYDfn4ws6Ra" title="Number of shares issued"&gt;400,409&lt;/span&gt; and recorded as an addition to equity for the issuance
of the common stock and treated as a reduction to equity as a cost of capital to be raised under the LP Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
2024 and 2023, the Company sold &lt;span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zYqdmdnM60C2" title="Sale of stock, shares"&gt;1,472,363&lt;/span&gt; and &lt;span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zLCbpnoNDMWf" title="Sale of stock, shares"&gt;2,125&lt;/span&gt; shares of common stock, respectively, under the LP Purchase Agreement, for net proceeds
of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_ztLngzWcHbmd"&gt;8,037,501&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zNFbGOrUlm72"&gt;449,227&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;At the Market
Offering&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
January 2023, the Company entered into the ATM Agreement with H.C. Wainwright &amp;amp; Co., LLC (HCW) pursuant to which the Company may
issue and sell, from time to time, shares of the Company&#x2019;s common stock having an aggregate offering price of up to $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn4n6_c20230101__20230131__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__srt--RangeAxis__srt--MaximumMember_znAQW9dAuinj"&gt;4.97&lt;/span&gt; million
in at-the-market offerings sales. HCW will act as sales agent and will be paid a &lt;span id="xdx_901_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20230101__20230131__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zrKOuWjmERn6" title="Sale of stock commission percent"&gt;3%&lt;/span&gt; commission on each sale under the ATM Agreement.
The Company&#x2019;s common stock will be sold at prevailing market prices at the time of the sale, and, as a result, prices will vary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
March 18, 2024, the Company increased the maximum aggregate offering price of the shares of the Company&#x2019;s common stock issuable
under the ATM Agreement from $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn4n6_c20240317__20240317__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvnaSx29XvMd"&gt;4.97&lt;/span&gt; million to $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn4n6_c20240318__20240318__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6urq9V7zY5k"&gt;8.47&lt;/span&gt; million and filed a prospectus supplement for an aggregate of $&lt;span id="xdx_903_ecustom--IncreaseInAggregateValue_pn5n6_c20240318__20240318__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHawWJpG8Oq5"&gt;3.5&lt;/span&gt; million. In connection
with the filing of the prospectus supplement, on March 17, 2024, the Company received a waiver from the purchaser in the February 2024
Offering under the securities purchase agreement, dated February 2, 2024, by and between the Company and such purchaser. In consideration
of the waiver set forth therein, the Company agreed to lower the exercise price of the Series A warrants to purchase up to an aggregate
of &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zBIBRk2XxoU7"&gt;28,855&lt;/span&gt; shares of common stock and Series B warrants to purchase up to an aggregate of &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zaeGDLMutLy3"&gt;14,428&lt;/span&gt; shares of common stock to $&lt;span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20240202__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR8Sj6A8BCug"&gt;13.56&lt;/span&gt;, which
warrants were previously issued by the Company to such purchaser on September 13, 2023 and to extend the exercise term of the Series
A warrants to March 17, 2029 and the term of the Series B warrants to March 17, 2026. The modifications to the warrants had no impact
on the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
August 19, 2024, the Company increased the maximum aggregate offering price of shares of the Company&#x2019;s common stock issuable under
the ATM Agreement from $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn4n6_c20240818__20240818__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTBVoJ4Yb7Rk"&gt;8.47&lt;/span&gt; million to $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn4n6_c20240819__20240819__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkqgxkRUW0Fd"&gt;11.33&lt;/span&gt; million and filed a prospectus supplement for an aggregate of $&lt;span id="xdx_907_ecustom--IncreaseInAggregateValue_pn4n6_c20240819__20240819__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2F2VamXprhj"&gt;2.86&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 3, 2024, the Company increased the maximum aggregate offering price of shares of the Company&#x2019;s common stock issuable
under the ATM Agreement from $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn4n6_c20240902__20240902__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zv9u66CErfse"&gt;11.33&lt;/span&gt; million to $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn4n6_c20240903__20240903__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmWLMcEgu69i"&gt;15.2&lt;/span&gt; million and filed a prospectus supplement for an aggregate of $&lt;span id="xdx_905_ecustom--IncreaseInAggregateValue_pn4n6_c20240903__20240903__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLxrNNtnQcTl"&gt;3.87&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
October 15, 2024, the Company increased the maximum aggregate offering price of shares of the Company&#x2019;s common stock issuable under
the ATM Agreement from $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241014__20241014__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR3NXRLUUmTl"&gt;15.2&lt;/span&gt; million to $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241015__20241015__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zW4TE5wOBMU"&gt;23.5&lt;/span&gt; million and filed a prospectus supplement for an aggregate of $&lt;span id="xdx_909_ecustom--IncreaseInAggregateValue_pn5n6_c20241015__20241015__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0zLzVQ0AIR6" title="Increase in aggregate value"&gt;8.3&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
2024 and 2023, the Company sold &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zWWUU3vUEDqk"&gt;983,093&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zYM3Q9Ggcjdg"&gt;6,868&lt;/span&gt; shares of common stock, respectively, under the ATM agreement, for net proceeds of
$&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zpnt2OVWpcyl"&gt;9,393,550&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zvWQUfGQ4gX1"&gt;1,745,737&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CING:SaleOfCommonStockTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-112023-08-11_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000797"
      unitRef="Shares">7597</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2023-08-11_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000799"
      unitRef="USDPShares">131.64</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-08-112023-08-11_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000801"
      unitRef="USD">1.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-11_custom_SeriesAandSeriesBWarrantsMember"
      decimals="INF"
      id="Fact000803"
      unitRef="Shares">7167</us-gaap:ClassOfWarrantOrRightOutstanding>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2023-09-11_custom_SeriesAandSeriesBWarrantsMember"
      decimals="INF"
      id="Fact000805"
      unitRef="USDPShares">138.62</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-11_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000807"
      unitRef="Shares">21688</us-gaap:ClassOfWarrantOrRightOutstanding>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2023-09-11_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000809"
      unitRef="USDPShares">138.62</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-11_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000811"
      unitRef="USDPShares">0.024</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentDescription contextRef="From2023-09-112023-09-11" id="Fact000813">The September 2023 Offering closed on
September 13, 2023. The pre-funded warrants were exercisable at any time after the date of issuance and had no expiration date. The holders
of pre-funded warrants could not exercise the warrants if the holder, together with its affiliates, would beneficially own more than
4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect
to such exercise.</us-gaap:DebtInstrumentDescription>
    <CING:GrossProceeds
      contextRef="From2023-09-112023-09-11"
      decimals="0"
      id="Fact000815"
      unitRef="USD">3999480</CING:GrossProceeds>
    <us-gaap:PaymentsForFees
      contextRef="From2023-09-112023-09-11"
      decimals="0"
      id="Fact000817"
      unitRef="USD">688929</us-gaap:PaymentsForFees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-02_custom_SeriesAandSeriesBWarrantsMember"
      decimals="INF"
      id="Fact000818"
      unitRef="Shares">114583</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-02_custom_SeriesAandSeriesBWarrantsMember"
      decimals="INF"
      id="Fact000819"
      unitRef="USDPShares">24.00</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-02-02_custom_PreFundedWarrantsMember_custom_SeriesAandSeriesBWarrantsMember"
      decimals="INF"
      id="Fact000820"
      unitRef="Shares">197917</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-02_custom_PreFundedWarrantsMember_custom_SeriesAandSeriesBWarrantsMember"
      decimals="INF"
      id="Fact000821"
      unitRef="USDPShares">23.988</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-02_custom_PreFundedWarrantsMember_custom_SeriesAandSeriesBWarrantsMember"
      decimals="INF"
      id="Fact000822"
      unitRef="USDPShares">0.0012</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentDescription contextRef="From2024-02-022024-02-02" id="Fact000823">The holders of pre-funded warrants could not exercise the warrants if the holder, together with its affiliates, would
beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately
after giving effect to such exercise. Each share of common stock and each pre-funded warrant were sold along with one Series A and 0.5
Series B warrants.</us-gaap:DebtInstrumentDescription>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-02-022024-02-02"
      decimals="-5"
      id="Fact000824"
      unitRef="USD">7500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsForFees
      contextRef="From2024-02-022024-02-02"
      decimals="0"
      id="Fact000825"
      unitRef="USD">750950</us-gaap:PaymentsForFees>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-08_custom_WFIAPreFundedWarrantsMember"
      decimals="INF"
      id="Fact000827"
      unitRef="Shares">28493</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-01-25_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="INF"
      id="Fact000828"
      unitRef="Shares">57254</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-03-31_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="INF"
      id="Fact000830"
      unitRef="Shares">588</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-06-28_custom_JuneTwentyTwentyFourWarrantsInducementMember"
      decimals="INF"
      id="Fact000832"
      unitRef="Shares">265625</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-28_custom_FebruaryTwentyTwentyFourWarrantsMember"
      decimals="INF"
      id="Fact000833"
      unitRef="USDPShares">7.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-06-28_us-gaap_CommonClassCMember"
      decimals="INF"
      id="Fact000834"
      unitRef="Shares">354167</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-06-28_custom_SeriesDCommonStockMember"
      decimals="INF"
      id="Fact000835"
      unitRef="Shares">177083</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-01-012024-12-31_custom_JuneTwentyTwentyFourWarrantsInducementMember"
      decimals="-5"
      id="Fact000836"
      unitRef="USD">1600000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-01-012024-12-31_custom_JuneTwentyTwentyFourWarrantsInducementMember"
      decimals="-5"
      id="Fact000838"
      unitRef="USD">2000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-012024-12-31_custom_JuneTwentyTwentyFourWarrantsInducementMember"
      decimals="-5"
      id="Fact000840"
      unitRef="USD">1600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-04-012023-04-30_custom_PurchaseAgreementMember_srt_MaximumMember"
      decimals="-6"
      id="Fact000842"
      unitRef="USD">12000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact000844"
      unitRef="USD">2685417</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000846"
      unitRef="Shares">1534</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact000848"
      unitRef="USD">400409</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000850"
      unitRef="Shares">1472363</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000852"
      unitRef="Shares">2125</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact000853"
      unitRef="USD">8037501</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact000854"
      unitRef="USD">449227</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-01-31_custom_ATMAgreementMember_custom_HCWainwrightAndCoLLCMember_srt_MaximumMember"
      decimals="-4"
      id="Fact000855"
      unitRef="USD">4970000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction
      contextRef="From2023-01-012023-01-31_custom_ATMAgreementMember_custom_HCWainwrightAndCoLLCMember"
      decimals="INF"
      id="Fact000857"
      unitRef="Pure">0.03</us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-03-172024-03-17_us-gaap_CommonStockMember"
      decimals="-4"
      id="Fact000858"
      unitRef="USD">4970000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-03-182024-03-18_us-gaap_CommonStockMember"
      decimals="-4"
      id="Fact000859"
      unitRef="USD">8470000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <CING:IncreaseInAggregateValue
      contextRef="From2024-03-182024-03-18_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact000860"
      unitRef="USD">3500000</CING:IncreaseInAggregateValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-02-02_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000861"
      unitRef="Shares">28855</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-02-02_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000862"
      unitRef="Shares">14428</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-02_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000863"
      unitRef="USDPShares">13.56</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-08-182024-08-18_us-gaap_CommonStockMember"
      decimals="-4"
      id="Fact000864"
      unitRef="USD">8470000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-08-192024-08-19_us-gaap_CommonStockMember"
      decimals="-4"
      id="Fact000865"
      unitRef="USD">11330000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <CING:IncreaseInAggregateValue
      contextRef="From2024-08-192024-08-19_us-gaap_CommonStockMember"
      decimals="-4"
      id="Fact000866"
      unitRef="USD">2860000</CING:IncreaseInAggregateValue>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-09-022024-09-02_us-gaap_CommonStockMember"
      decimals="-4"
      id="Fact000867"
      unitRef="USD">11330000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-09-032024-09-03_us-gaap_CommonStockMember"
      decimals="-4"
      id="Fact000868"
      unitRef="USD">15200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <CING:IncreaseInAggregateValue
      contextRef="From2024-09-032024-09-03_us-gaap_CommonStockMember"
      decimals="-4"
      id="Fact000869"
      unitRef="USD">3870000</CING:IncreaseInAggregateValue>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-142024-10-14_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact000870"
      unitRef="USD">15200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-10-152024-10-15_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact000871"
      unitRef="USD">23500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <CING:IncreaseInAggregateValue
      contextRef="From2024-10-152024-10-15_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact000873"
      unitRef="USD">8300000</CING:IncreaseInAggregateValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMAgreementMember"
      decimals="INF"
      id="Fact000874"
      unitRef="Shares">983093</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMAgreementMember"
      decimals="INF"
      id="Fact000875"
      unitRef="Shares">6868</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMAgreementMember"
      decimals="0"
      id="Fact000876"
      unitRef="USD">9393550</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMAgreementMember"
      decimals="0"
      id="Fact000877"
      unitRef="USD">1745737</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <CING:CommonStockPurchaseWarrantsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000879">&lt;p id="xdx_805_ecustom--CommonStockPurchaseWarrantsTextBlock_z2KgjGSmnbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;b&gt;(11)
&lt;span id="xdx_826_zTYJYZWW4Q73"&gt;Common Stock Purchase Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Initial
Public Offering&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
each of the &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zCbkHClafRg6" title="Number of warrants issued, shares"&gt;17,361&lt;/span&gt; shares of common stock issued in connection with the Company&#x2019;s IPO, one common stock purchase warrant was also
issued and included in the unit price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zcpE1DGRywH4" title="Purchase of warrants price per share"&gt;1,440.00&lt;/span&gt;. These warrants were immediately separable and tradeable. The underwriters purchased
&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zYfvaijIgXKh" title="Purchase of warrants shares"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z4MSwbSMZ1Vh" title="Purchase of warrants shares"&gt;2,604&lt;/span&gt;&lt;/span&gt; additional common stock purchase warrants for $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zDSCVGT5FZG" title="Purchase of warrants price per share"&gt;.012&lt;/span&gt; per warrant less underwriting discounts and commissions. These &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEnpt0YaQxui" title="Purchase of warrants shares"&gt;19,965&lt;/span&gt; common
stock purchase warrants have an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9pvuGClQWjl" title="Purchase of warrants price per share"&gt;1,440.00&lt;/span&gt; per share and are &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231_zjUPoOj4pFc7" title="Warrants exercisable, description"&gt;exercisable from December 10, 2021 through December 10,
2026.&lt;/span&gt; Upon the termination date, these warrants will be automatically exercised via a cashless exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
addition to the common stock purchase warrants noted above, the Company issued &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zmmQx8fD7u1e" title="Purchase of warrants shares"&gt;868&lt;/span&gt; common stock purchase warrants to the underwriters
for the Company&#x2019;s IPO pursuant to the underwriting agreement. These warrants have an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvbG2E5SFv7c" title="Purchase of warrants price per share"&gt;1,800.00&lt;/span&gt; per share and
provide for a cashless exercise feature. These &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_znNT1QWPD0Fb" title="Warrants exercisable, description"&gt;warrants are exercisable from June 7, 2023 through December 10, 2026.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;September
2023 Offering&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
each of the &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGp8ImuAHI6b" title="Number of warrants issued, shares"&gt;28,855&lt;/span&gt; shares of common stock and pre-funded warrants issued in the September 2023 Offering, the Company issued Series A
warrants to purchase up to &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantMember_zORqR9EwD68d" title="Number of warrants issued, shares"&gt;28,855&lt;/span&gt; shares of common stock and Series B warrants to purchase up to &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantMember_zLsTJQKZD9Fh" title="Number of warrants issued, shares"&gt;14,428&lt;/span&gt; shares of common stock. The Series
A and Series B warrants had an original exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantMember_zCGgGhLxuSq4" title="Exercise price"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantMember_zi8CEIQSI1ml" title="Exercise price"&gt;138.62&lt;/span&gt; &lt;/span&gt;per share and became exercisable on the effective date of stockholder
approval of the shares issuable pursuant to the warrants. In connection with the waiver granted in March 2024 by the purchaser in the
February 2024 Offering to allow the Company to file a prospectus supplement to increase the maximum aggregate offering price of shares
of the Company&#x2019;s common stock issuable under the ATM Agreement, the exercise price of the Series A and Series B warrants was lowered
to $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAandSeriesBWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zqrEahMZm8f6" title="Exercise price"&gt;13.56&lt;/span&gt; per share and the term of the Series A warrants was extended to March 17, 2029 and the term of the Series B warrants was extended
to March 17, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company valued the pre-funded warrants to purchase &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z5hnhGYR1WXg" title="Number of warrants"&gt;21,688&lt;/span&gt; shares of common stock based on their issuance date fair value of $&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zGO3ZntDpVof" title="Issuance Date Fair Value Total"&gt;3,006,008&lt;/span&gt;.
As of December 31, 2023, all of the pre-funded warrants relating to the September 2023 Offering had been exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
connection with the September 2023 Offering, the Company issued placement agent warrants to purchase up to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zR3RMq3xES2i" title="Number of warrants"&gt;1,443&lt;/span&gt; shares of common stock.
The placement agent warrants have an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zhl46F3onwV7" title="Warrant exercise price"&gt;173.28&lt;/span&gt; per share. These warrants have a five-year term ending September 11, 2028.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
gross proceeds of the September 2023 public offering was allocated to the common stock and common stock purchase warrants using the relative
fair value method shown as follows. Fair value of the warrants was recorded to Additional Paid-in-Capital on the Company&#x2019;s balance
sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfFairValueOfWarrantsToAdditionalPaidInCapitalTableTextBlock_gL3SOFVOWTAPI-KCWLF_zm5cKWFYAQV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zcmZHKSoOpgd" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Fair Value of the Warrants to Additional Paid in Capital&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;of Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Allocated&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Common Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zv5IZ0jxFmg9" style="width: 12%; text-align: right" title="Fair value"&gt;993,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_z1mRXSqlJo5f" style="width: 12%; text-align: right" title="Percent of Total Fair Value"&gt;10.6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AmountAllocated_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_z4xL2ONeccf8" style="width: 12%; text-align: right" title="Amount Allocated"&gt;423,945&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Pre-Funded Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zHn9ARFLh3bc" style="text-align: right" title="Fair value"&gt;3,006,003&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zPrJ3Nm4Lt48" style="text-align: right" title="Percent of Total Fair Value"&gt;32.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AmountAllocated_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zwzP4eHzpcAh" style="text-align: right" title="Amount Allocated"&gt;1,279,833&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Series A, B and Placement Agent Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesABPlacementAgentWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zjjUfVJRCrK4" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value"&gt;5,388,376&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesABPlacementAgentWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_z5ro2JmHCJ1d" style="border-bottom: Black 1pt solid; text-align: right" title="Percent of Total Fair Value"&gt;57.4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AmountAllocated_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesABPlacementAgentWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zl4R0waZkoek" style="border-bottom: Black 1pt solid; text-align: right" title="Amount Allocated"&gt;2,295,701&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zD9QQvbs0uub" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;9,387,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zv0MGYjhOxP2" style="border-bottom: Black 2.5pt double; text-align: right" title="Percent of Total Fair Value"&gt;100.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AmountAllocated_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zjJyImy9Hcbe" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount Allocated"&gt;3,999,479&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A0_z7G8KVUJqbz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;February
2024 Offering&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
the &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240202__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zKLBofC0lxh" title="Prefunded warrants"&gt;312,500&lt;/span&gt; shares of common stock and pre-funded warrants issued in the February 2024 Offering, the Company issued Series A warrants
to purchase up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zVcdKiyLmS8i" title="Prefunded warrants"&gt;312,500&lt;/span&gt; shares of common stock and Series B warrants to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zajHFAjOgOh8" title="Prefunded warrants"&gt;156,250&lt;/span&gt; shares of common stock. The Series A
and Series B warrants have an exercise price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zMVbYFE560a5" title="Warrants, exercise price"&gt;24.00&lt;/span&gt; per share and became exercisable immediately. The Series A warrants have a &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240205__20240205__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zCebECTub2Cb" title="Warrants term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0959"&gt;five&lt;/span&gt;&lt;/span&gt;-year
term and the Series B warrants have a&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240205__20240205__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zcO3buFWbaBc" title="Warrants term::XDX::P2Y"&gt; &lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;two&lt;/span&gt;&lt;/span&gt;-year term from the initial exercise date of February 5, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company evaluated the pre-funded warrants and the Series A and B warrants for liability or equity classification in accordance with the
provisions of ASC Topic 480, &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;, and ASC Topic 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;, and determined
that equity treatment was appropriate. The Company valued the pre-funded warrants to purchase &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zjrhL9jmHYq1" title="Warrants outstanding"&gt;197,917&lt;/span&gt; shares of common stock based on
their issuance date fair value of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--PrefundedWarrantsMember_zMMClmdPSJsj"&gt;24.00&lt;/span&gt;. As of December 31, 2024, all of the pre-funded warrants had been exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
connection with the February 2024 Offering, the Company issued placement agent warrants to purchase up to &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zF0264vwo0Qd" title="Prefunded warrants"&gt;12,500&lt;/span&gt; shares of common stock.
The placement agent warrants have an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zXDssxmQ0Yaa" title="Warrants, exercise price"&gt;30.00&lt;/span&gt; per share. These warrants have a &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240202__20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zrj2SdurmeG3" title="Warrants term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0970"&gt;five&lt;/span&gt;&lt;/span&gt;-year term ending February 2, 2029.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Series A,
Series B and placement agent warrants issued in the September 2023 Offering and the February 2024 Offering were valued using a Black-Scholes
model with a risk-free rate of &lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240202__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zbfkZCegfR1h"&gt;4.5%&lt;/span&gt;-&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240202__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_ztTsA5hXeP"&gt;5.3%&lt;/span&gt;, the respective terms of &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240202__20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zVS4jlan2Imi" title="::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;five&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dc_c20240202__20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zTlkf3YjjAQ5"&gt;two years&lt;/span&gt;, and a volatility of &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20240202__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zf9SGiV9QKLg"&gt;1.29&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20240202__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zaWg0SesEsA3"&gt;1.32&lt;/span&gt;. The estimated volatility
of the Company&#x2019;s common stock at the date of measurement is based on an average historical stock price volatility of comparable
public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends
as the Company does not have sufficient trading history for its common stock. The risk-free rate is based on the expected term of the
warrants based on the constant maturity of U.S. Treasury securities with similar maturities as of the date of grant. The expected term
has been estimated using the contractual term of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
gross proceeds of the February 2024 public offering was allocated to the common stock and common stock purchase warrants using the relative
fair value method shown as follows. Fair value of the warrants was recorded to Additional Paid-in-Capital on the Company&#x2019;s balance
sheet.&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C0B_gL3SOFVOWTAPI-KCWLF_zt1evpumfKb1"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_302_134_zslVzr1Q6eWf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Fair Value of the Warrants to Additional Paid in Capital (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;of Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Allocated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zMPLVv0FVlOf" style="width: 12%; text-align: right" title="Fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,750,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zw8DCphugxAc" style="width: 12%; text-align: right" title="Percent of Total Fair Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--AmountAllocated_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_z3NRyleoAHt7" style="width: 12%; text-align: right" title="Amount Allocated"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,987,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zrchdwsnT262" style="text-align: right" title="Fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,750,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zpsfelMBP59h" style="text-align: right" title="Percent of Total Fair Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--AmountAllocated_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zBGxlvOMICpi" style="text-align: right" title="Amount Allocated"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,435,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series A, B and Placement
    Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesABPlacementAgentWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zhh5hF54CZ41" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,878,123&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesABPlacementAgentWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zmejMTjUqsbd" style="border-bottom: Black 1pt solid; text-align: right" title="Percent of Total Fair Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27.7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AmountAllocated_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesABPlacementAgentWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_z7FKcoALtQpa" style="border-bottom: Black 1pt solid; text-align: right" title="Amount Allocated"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,077,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_z7YLqAhbNGGh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,378,123&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zwlQPiKa9zS9" style="border-bottom: Black 2.5pt double; text-align: right" title="Percent of Total Fair Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AmountAllocated_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_z2fjQlL1pJFg" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount Allocated"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_C04_gL3SOFVOWTAPI-KCWLF_zcODdtbaxwX1"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Certain
of the Series A and Series B warrants issued in connection with the February 2024 Offering were exercised as part of the June 2024 Warrant
Inducement as described in Note 10. Series C and Series D warrants were issued as part of the June 2024 Warrant Inducement, which closed
on July 1, 2024. The Series C and Series D warrants have an exercise price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240202__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCAndSeriesDWarrantsMember_zekBJ85eH7R4" title="Warrants, exercise price"&gt;7.02&lt;/span&gt; per share and became exercisable on the effective
date of stockholder approval of the shares issuable pursuant to the warrants. The Series C warrants have a five-year term and the Series
D warrants have a two-year term from the initial exercise date of August 28, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zCoEbGGj653d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the Company&#x2019;s outstanding common stock purchase warrants as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zbqKyDuNTTtc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Warrants and Rights Outstanding&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;per
    Warrant&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 2021 Initial Public Offering
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember_zd4TxPd8bZZg" style="width: 12%; text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,965&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember_zQDjGBw9Q333" style="width: 12%; text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,440.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember_z27nvhlhcSu1" style="width: 12%; text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,144.80&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember_zYMiiMUrFBJl" style="width: 12%; text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,855,932&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 2021 Underwriter Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneUnderwriterWarrantsMember_z4udqaO7sxzd" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;868&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneUnderwriterWarrantsMember_zCVoYbBs52wg" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,800.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneUnderwriterWarrantsMember_znhzwnYGFuQc" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,113.48&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneUnderwriterWarrantsMember_z7rMqhRBW0m6" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;966,501&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September 2023 Public Offering Series A Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember_zaCbI5DBv243" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,855&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember_zbDkSTR0afa2" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.56&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember_zfMwRVjE1Rwj" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;129.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember_zAnw4J6aiPmf" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,746,533&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September 2023 Public Offering Series B Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember_zf24rXi2qDTi" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,428&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember_zb1aLDXXg7Pk" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.56&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember_zKIokHhbmSP8" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;101.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember_z5ihUSLSCCp5" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,457,805&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September 2023 Placement Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember_zy8EXl6cqIBk" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,443&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember_z0TmMQQf9Sw4" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;172.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember_z1EAS5yTgGq7" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;127.56&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember_zAz39FCRe66" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;184,069&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;February 2024 Public Offering Series A Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember_zZPmU7T60ko8" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135,417&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember_zyNe6A2mAtMc" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember_zpI5MxKvl3n8" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember_zoGt51wQYqah" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,901,255&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;February 2024 Public Offering Series B Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember_zXsjUbMsCxz6" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;67,708&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember_zqATiQLCFFyb" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember_zo2drspkzkok" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.88&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember_zocJdLrnDHe1" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;804,371&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;February 2024 Placement Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember_znsgX9nUmEK4" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember_znWpjoLEt0I9" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember_zVKbNJGqX33i" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember_zx72yAEcLhDi" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;172,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;July 2024 Series C Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesCWarrantsMember_zKBD5naXdEYi" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;354,167&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesCWarrantsMember_zaGK9LQcglo7" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.02&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesCWarrantsMember_zO05e3slEUSd" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesCWarrantsMember_zxi8xLAGbl28" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,147,501&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;July 2024 Series D Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesDWarrantsMember_zttp4RZjZX6" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;177,083&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesDWarrantsMember_zB49kJeZjEU8" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.02&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesDWarrantsMember_zRZF7ogiNgN3" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesDWarrantsMember_zFlkb7oz95i7" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;424,999&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;July 2024 Placement Agent
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyTwoThousandTwentyFourPlacementAgentWarrantsMember_z6vZ97LUgfMi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,250&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyTwoThousandTwentyFourPlacementAgentWarrantsMember_zcyBV8vUaBg" style="padding-bottom: 1pt; text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.78&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyTwoThousandTwentyFourPlacementAgentWarrantsMember_zXckFsCcoeMk" style="padding-bottom: 1pt; text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.23&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyTwoThousandTwentyFourPlacementAgentWarrantsMember_zMb3WrwpFfYa" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47,388&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance- December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zNutolsdsnj4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;833,684&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231_z97bpfhKV8Xj" style="border-bottom: Black 2.5pt double; text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33,708,854&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zL4nldmw1tyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CING:CommonStockPurchaseWarrantsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000881"
      unitRef="Shares">17361</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000883"
      unitRef="USDPShares">1440.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact000885"
      unitRef="Shares">2604</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact000887"
      unitRef="Shares">2604</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact000889"
      unitRef="USDPShares">0.012</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000891"
      unitRef="Shares">19965</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000893"
      unitRef="USDPShares">1440.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2024-01-01to2024-12-31" id="Fact000895">exercisable from December 10, 2021 through December 10,
2026.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000897"
      unitRef="Shares">868</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000899"
      unitRef="USDPShares">1800.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="From2024-01-012024-12-31_us-gaap_IPOMember"
      id="Fact000901">warrants are exercisable from June 7, 2023 through December 10, 2026.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000903"
      unitRef="Shares">28855</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-09-30_custom_SeriesAWarrantMember"
      decimals="INF"
      id="Fact000905"
      unitRef="Shares">28855</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-09-30_custom_SeriesBWarrantMember"
      decimals="INF"
      id="Fact000907"
      unitRef="Shares">14428</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-30_custom_SeriesBWarrantMember"
      decimals="INF"
      id="Fact000909"
      unitRef="USDPShares">138.62</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-30_custom_SeriesBWarrantMember"
      decimals="INF"
      id="Fact000911"
      unitRef="USDPShares">138.62</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesAandSeriesBWarrantsMember_custom_ATMAgreementMember"
      decimals="INF"
      id="Fact000913"
      unitRef="USDPShares">13.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000915"
      unitRef="Shares">21688</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember"
      decimals="0"
      id="Fact000917"
      unitRef="USD">3006008</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-30_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000919"
      unitRef="Shares">1443</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-30_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000921"
      unitRef="USDPShares">173.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CING:ScheduleOfFairValueOfWarrantsToAdditionalPaidInCapitalTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000925">&lt;p id="xdx_89F_ecustom--ScheduleOfFairValueOfWarrantsToAdditionalPaidInCapitalTableTextBlock_gL3SOFVOWTAPI-KCWLF_zm5cKWFYAQV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zcmZHKSoOpgd" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Fair Value of the Warrants to Additional Paid in Capital&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Percent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;of Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Allocated&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Common Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zv5IZ0jxFmg9" style="width: 12%; text-align: right" title="Fair value"&gt;993,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_z1mRXSqlJo5f" style="width: 12%; text-align: right" title="Percent of Total Fair Value"&gt;10.6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AmountAllocated_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_z4xL2ONeccf8" style="width: 12%; text-align: right" title="Amount Allocated"&gt;423,945&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Pre-Funded Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zHn9ARFLh3bc" style="text-align: right" title="Fair value"&gt;3,006,003&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zPrJ3Nm4Lt48" style="text-align: right" title="Percent of Total Fair Value"&gt;32.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AmountAllocated_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zwzP4eHzpcAh" style="text-align: right" title="Amount Allocated"&gt;1,279,833&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Series A, B and Placement Agent Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesABPlacementAgentWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zjjUfVJRCrK4" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value"&gt;5,388,376&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesABPlacementAgentWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_z5ro2JmHCJ1d" style="border-bottom: Black 1pt solid; text-align: right" title="Percent of Total Fair Value"&gt;57.4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AmountAllocated_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesABPlacementAgentWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zl4R0waZkoek" style="border-bottom: Black 1pt solid; text-align: right" title="Amount Allocated"&gt;2,295,701&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zD9QQvbs0uub" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;9,387,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zv0MGYjhOxP2" style="border-bottom: Black 2.5pt double; text-align: right" title="Percent of Total Fair Value"&gt;100.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AmountAllocated_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingMember_zjJyImy9Hcbe" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount Allocated"&gt;3,999,479&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_302_134_zslVzr1Q6eWf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Fair Value of the Warrants to Additional Paid in Capital (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Percent&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;of Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Allocated&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zMPLVv0FVlOf" style="width: 12%; text-align: right" title="Fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,750,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zw8DCphugxAc" style="width: 12%; text-align: right" title="Percent of Total Fair Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--AmountAllocated_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_z3NRyleoAHt7" style="width: 12%; text-align: right" title="Amount Allocated"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,987,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zrchdwsnT262" style="text-align: right" title="Fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,750,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zpsfelMBP59h" style="text-align: right" title="Percent of Total Fair Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--AmountAllocated_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zBGxlvOMICpi" style="text-align: right" title="Amount Allocated"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,435,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series A, B and Placement
    Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesABPlacementAgentWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zhh5hF54CZ41" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,878,123&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesABPlacementAgentWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zmejMTjUqsbd" style="border-bottom: Black 1pt solid; text-align: right" title="Percent of Total Fair Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27.7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AmountAllocated_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--SeriesABPlacementAgentWarrantsMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_z7FKcoALtQpa" style="border-bottom: Black 1pt solid; text-align: right" title="Amount Allocated"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,077,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_z7YLqAhbNGGh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,378,123&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--EquityFairValuePercentage_iI_dp_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_zwlQPiKa9zS9" style="border-bottom: Black 2.5pt double; text-align: right" title="Percent of Total Fair Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AmountAllocated_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingMember_z2fjQlL1pJFg" style="border-bottom: Black 2.5pt double; text-align: right" title="Amount Allocated"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;</CING:ScheduleOfFairValueOfWarrantsToAdditionalPaidInCapitalTableTextBlock>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember"
      decimals="0"
      id="Fact000927"
      unitRef="USD">993472</us-gaap:FairValueAdjustmentOfWarrants>
    <CING:EquityFairValuePercentage
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember"
      decimals="INF"
      id="Fact000929"
      unitRef="Pure">0.106</CING:EquityFairValuePercentage>
    <CING:AmountAllocated
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember"
      decimals="0"
      id="Fact000931"
      unitRef="USD">423945</CING:AmountAllocated>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_PreFundedWarrantsMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember"
      decimals="0"
      id="Fact000933"
      unitRef="USD">3006003</us-gaap:FairValueAdjustmentOfWarrants>
    <CING:EquityFairValuePercentage
      contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember"
      decimals="INF"
      id="Fact000935"
      unitRef="Pure">0.320</CING:EquityFairValuePercentage>
    <CING:AmountAllocated
      contextRef="From2024-01-012024-12-31_custom_PreFundedWarrantsMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember"
      decimals="0"
      id="Fact000937"
      unitRef="USD">1279833</CING:AmountAllocated>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_SeriesABPlacementAgentWarrantsMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember"
      decimals="0"
      id="Fact000939"
      unitRef="USD">5388376</us-gaap:FairValueAdjustmentOfWarrants>
    <CING:EquityFairValuePercentage
      contextRef="AsOf2024-12-31_custom_SeriesABPlacementAgentWarrantsMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember"
      decimals="INF"
      id="Fact000941"
      unitRef="Pure">0.574</CING:EquityFairValuePercentage>
    <CING:AmountAllocated
      contextRef="From2024-01-012024-12-31_custom_SeriesABPlacementAgentWarrantsMember_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember"
      decimals="0"
      id="Fact000943"
      unitRef="USD">2295701</CING:AmountAllocated>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember"
      decimals="0"
      id="Fact000945"
      unitRef="USD">9387851</us-gaap:FairValueAdjustmentOfWarrants>
    <CING:EquityFairValuePercentage
      contextRef="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember"
      decimals="INF"
      id="Fact000947"
      unitRef="Pure">1.000</CING:EquityFairValuePercentage>
    <CING:AmountAllocated
      contextRef="From2024-01-012024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingMember"
      decimals="0"
      id="Fact000949"
      unitRef="USD">3999479</CING:AmountAllocated>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-02_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000951"
      unitRef="Shares">312500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-02_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000953"
      unitRef="Shares">312500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-02_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000955"
      unitRef="Shares">156250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-02_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000957"
      unitRef="USDPShares">24.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-02-02_custom_PreFundedWarrantsMember16237265"
      decimals="INF"
      id="Fact000963"
      unitRef="Shares">197917</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-02_custom_PreFundedWarrantsMember16237265"
      decimals="INF"
      id="Fact000964"
      unitRef="USDPShares">24.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-02-02_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000966"
      unitRef="Shares">12500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-02_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000968"
      unitRef="USDPShares">30.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-02-02_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000971"
      unitRef="Pure">4.05</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-02-02_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000972"
      unitRef="Pure">5.03</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-02-022024-02-02_custom_SeriesBWarrantsMember"
      id="Fact000974">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-02-02_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000975"
      unitRef="Pure">0.0129</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-02-02_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000976"
      unitRef="Pure">0.0132</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember"
      decimals="0"
      id="Fact000978"
      unitRef="USD">2750000</us-gaap:FairValueAdjustmentOfWarrants>
    <CING:EquityFairValuePercentage
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember"
      decimals="INF"
      id="Fact000980"
      unitRef="Pure">0.265</CING:EquityFairValuePercentage>
    <CING:AmountAllocated
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember"
      decimals="0"
      id="Fact000982"
      unitRef="USD">1987500</CING:AmountAllocated>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_PreFundedWarrantsMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember"
      decimals="0"
      id="Fact000984"
      unitRef="USD">4750000</us-gaap:FairValueAdjustmentOfWarrants>
    <CING:EquityFairValuePercentage
      contextRef="AsOf2024-12-31_custom_PreFundedWarrantsMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember"
      decimals="INF"
      id="Fact000986"
      unitRef="Pure">0.458</CING:EquityFairValuePercentage>
    <CING:AmountAllocated
      contextRef="From2024-01-012024-12-31_custom_PreFundedWarrantsMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember"
      decimals="0"
      id="Fact000988"
      unitRef="USD">3435000</CING:AmountAllocated>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_SeriesABPlacementAgentWarrantsMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember"
      decimals="0"
      id="Fact000990"
      unitRef="USD">2878123</us-gaap:FairValueAdjustmentOfWarrants>
    <CING:EquityFairValuePercentage
      contextRef="AsOf2024-12-31_custom_SeriesABPlacementAgentWarrantsMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember"
      decimals="INF"
      id="Fact000992"
      unitRef="Pure">0.277</CING:EquityFairValuePercentage>
    <CING:AmountAllocated
      contextRef="From2024-01-012024-12-31_custom_SeriesABPlacementAgentWarrantsMember_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember"
      decimals="0"
      id="Fact000994"
      unitRef="USD">2077500</CING:AmountAllocated>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember"
      decimals="0"
      id="Fact000996"
      unitRef="USD">10378123</us-gaap:FairValueAdjustmentOfWarrants>
    <CING:EquityFairValuePercentage
      contextRef="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember"
      decimals="INF"
      id="Fact000998"
      unitRef="Pure">1.000</CING:EquityFairValuePercentage>
    <CING:AmountAllocated
      contextRef="From2024-01-012024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingMember"
      decimals="0"
      id="Fact001000"
      unitRef="USD">7500000</CING:AmountAllocated>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-02_custom_SeriesCAndSeriesDWarrantsMember"
      decimals="INF"
      id="Fact001002"
      unitRef="USDPShares">7.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001004">&lt;p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zCoEbGGj653d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the Company&#x2019;s outstanding common stock purchase warrants as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zbqKyDuNTTtc" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Warrants and Rights Outstanding&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;per
    Warrant&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 2021 Initial Public Offering
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember_zd4TxPd8bZZg" style="width: 12%; text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,965&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember_zQDjGBw9Q333" style="width: 12%; text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,440.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember_z27nvhlhcSu1" style="width: 12%; text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,144.80&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember_zYMiiMUrFBJl" style="width: 12%; text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,855,932&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 2021 Underwriter Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneUnderwriterWarrantsMember_z4udqaO7sxzd" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;868&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneUnderwriterWarrantsMember_zCVoYbBs52wg" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,800.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneUnderwriterWarrantsMember_znhzwnYGFuQc" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,113.48&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--DecemberTwoThousandTwentyOneUnderwriterWarrantsMember_z7rMqhRBW0m6" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;966,501&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September 2023 Public Offering Series A Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember_zaCbI5DBv243" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,855&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember_zbDkSTR0afa2" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.56&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember_zfMwRVjE1Rwj" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;129.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember_zAnw4J6aiPmf" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,746,533&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September 2023 Public Offering Series B Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember_zf24rXi2qDTi" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,428&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember_zb1aLDXXg7Pk" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.56&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember_zKIokHhbmSP8" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;101.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember_z5ihUSLSCCp5" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,457,805&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September 2023 Placement Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember_zy8EXl6cqIBk" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,443&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember_z0TmMQQf9Sw4" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;172.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember_z1EAS5yTgGq7" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;127.56&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember_zAz39FCRe66" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;184,069&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;February 2024 Public Offering Series A Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember_zZPmU7T60ko8" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135,417&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember_zyNe6A2mAtMc" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember_zpI5MxKvl3n8" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.04&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember_zoGt51wQYqah" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,901,255&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;February 2024 Public Offering Series B Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember_zXsjUbMsCxz6" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;67,708&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember_zqATiQLCFFyb" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember_zo2drspkzkok" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.88&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember_zocJdLrnDHe1" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;804,371&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;February 2024 Placement Agent Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember_znsgX9nUmEK4" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember_znWpjoLEt0I9" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember_zVKbNJGqX33i" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember_zx72yAEcLhDi" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;172,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;July 2024 Series C Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesCWarrantsMember_zKBD5naXdEYi" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;354,167&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesCWarrantsMember_zaGK9LQcglo7" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.02&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesCWarrantsMember_zO05e3slEUSd" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesCWarrantsMember_zxi8xLAGbl28" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,147,501&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;July 2024 Series D Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesDWarrantsMember_zttp4RZjZX6" style="text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;177,083&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesDWarrantsMember_zB49kJeZjEU8" style="text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.02&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesDWarrantsMember_zRZF7ogiNgN3" style="text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyFourSeriesDWarrantsMember_zFlkb7oz95i7" style="text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;424,999&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;July 2024 Placement Agent
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyTwoThousandTwentyFourPlacementAgentWarrantsMember_z6vZ97LUgfMi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,250&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyTwoThousandTwentyFourPlacementAgentWarrantsMember_zcyBV8vUaBg" style="padding-bottom: 1pt; text-align: right" title="Exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.78&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ClassOfWarrantOrRightFairValuePerWarrants_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyTwoThousandTwentyFourPlacementAgentWarrantsMember_zXckFsCcoeMk" style="padding-bottom: 1pt; text-align: right" title="Issuance Date Fair Value Per Warrant"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.23&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyTwoThousandTwentyFourPlacementAgentWarrantsMember_zMb3WrwpFfYa" style="border-bottom: Black 1pt solid; text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47,388&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance- December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zNutolsdsnj4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;833,684&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iI_c20241231_z97bpfhKV8Xj" style="border-bottom: Black 2.5pt double; text-align: right" title="Issuance Date Fair Value Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33,708,854&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember"
      decimals="INF"
      id="Fact001006"
      unitRef="Shares">19965</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember"
      decimals="INF"
      id="Fact001008"
      unitRef="USDPShares">1440.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember"
      decimals="INF"
      id="Fact001010"
      unitRef="USDPShares">1144.80</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyOneInitialPublicOfferingWarrantsMember"
      decimals="0"
      id="Fact001012"
      unitRef="USD">22855932</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyOneUnderwriterWarrantsMember"
      decimals="INF"
      id="Fact001014"
      unitRef="Shares">868</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyOneUnderwriterWarrantsMember"
      decimals="INF"
      id="Fact001016"
      unitRef="USDPShares">1800.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyOneUnderwriterWarrantsMember"
      decimals="INF"
      id="Fact001018"
      unitRef="USDPShares">1113.48</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_custom_DecemberTwoThousandTwentyOneUnderwriterWarrantsMember"
      decimals="0"
      id="Fact001020"
      unitRef="USD">966501</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember"
      decimals="INF"
      id="Fact001022"
      unitRef="Shares">28855</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember"
      decimals="INF"
      id="Fact001024"
      unitRef="USDPShares">13.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember"
      decimals="INF"
      id="Fact001026"
      unitRef="USDPShares">129.84</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingSeriesAWarrantsMember"
      decimals="0"
      id="Fact001028"
      unitRef="USD">3746533</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember"
      decimals="INF"
      id="Fact001030"
      unitRef="Shares">14428</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember"
      decimals="INF"
      id="Fact001032"
      unitRef="USDPShares">13.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember"
      decimals="INF"
      id="Fact001034"
      unitRef="USDPShares">101.04</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePublicOfferingSeriesBWarrantsMember"
      decimals="0"
      id="Fact001036"
      unitRef="USD">1457805</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001038"
      unitRef="Shares">1443</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001040"
      unitRef="USDPShares">172.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001042"
      unitRef="USDPShares">127.56</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_custom_SeptemberTwoThousandTwentyThreePlacementAgentWarrantsMember"
      decimals="0"
      id="Fact001044"
      unitRef="USD">184069</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember"
      decimals="INF"
      id="Fact001046"
      unitRef="Shares">135417</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember"
      decimals="INF"
      id="Fact001048"
      unitRef="USDPShares">24.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember"
      decimals="INF"
      id="Fact001050"
      unitRef="USDPShares">14.04</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingSeriesAWarrantsMember"
      decimals="0"
      id="Fact001052"
      unitRef="USD">1901255</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember"
      decimals="INF"
      id="Fact001054"
      unitRef="Shares">67708</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember"
      decimals="INF"
      id="Fact001056"
      unitRef="USDPShares">24.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember"
      decimals="INF"
      id="Fact001058"
      unitRef="USDPShares">11.88</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPublicOfferingSeriesBWarrantsMember"
      decimals="0"
      id="Fact001060"
      unitRef="USD">804371</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001062"
      unitRef="Shares">12500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001064"
      unitRef="USDPShares">30.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001066"
      unitRef="USDPShares">13.80</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_custom_FebruaryTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="0"
      id="Fact001068"
      unitRef="USD">172500</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyFourSeriesCWarrantsMember"
      decimals="INF"
      id="Fact001070"
      unitRef="Shares">354167</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyFourSeriesCWarrantsMember"
      decimals="INF"
      id="Fact001072"
      unitRef="USDPShares">7.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyFourSeriesCWarrantsMember"
      decimals="INF"
      id="Fact001074"
      unitRef="USDPShares">3.24</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyFourSeriesCWarrantsMember"
      decimals="0"
      id="Fact001076"
      unitRef="USD">1147501</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyFourSeriesDWarrantsMember"
      decimals="INF"
      id="Fact001078"
      unitRef="Shares">177083</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyFourSeriesDWarrantsMember"
      decimals="INF"
      id="Fact001080"
      unitRef="USDPShares">7.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyFourSeriesDWarrantsMember"
      decimals="INF"
      id="Fact001082"
      unitRef="USDPShares">2.40</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyFourSeriesDWarrantsMember"
      decimals="0"
      id="Fact001084"
      unitRef="USD">424999</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_JulyTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001086"
      unitRef="Shares">21250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_JulyTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001088"
      unitRef="USDPShares">8.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CING:ClassOfWarrantOrRightFairValuePerWarrants
      contextRef="AsOf2024-12-31_custom_JulyTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001090"
      unitRef="USDPShares">2.23</CING:ClassOfWarrantOrRightFairValuePerWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_custom_JulyTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="0"
      id="Fact001092"
      unitRef="USD">47388</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001094"
      unitRef="Shares">833684</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001096"
      unitRef="USD">33708854</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001098">&lt;p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zrX0WWcDMrke" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(12) &lt;span id="xdx_824_z0HgEmZUBKob"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
September 2021, the Company&#x2019;s board of directors and stockholders adopted the 2021 Equity Incentive Plan ( 2021 Plan), which provides
for the grant of incentive stock options and non-qualified stock options to purchase shares of the Company&#x2019;s common stock, stock
appreciation rights, restricted stock units, restricted or unrestricted shares of common stock, performance shares, performance units,
incentive bonus awards, other stock-based awards and other cash-based awards. No awards may be made under the 2021 Plan on or after September
24, 2031, but the 2021 Plan will continue thereafter while previously granted awards remain outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
the Company&#x2019;s 2024 annual meeting, shareholders approved an amendment to the 2021 Plan to increase the number of shares of common
stock authorized for issuance thereunder by &lt;span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20240531__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zleG4xUxBCk4" title="Common stock, shares authorized"&gt;104,167&lt;/span&gt; shares to &lt;span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwwCGemXs5s9" title="Common stock, shares authorized"&gt;125,577&lt;/span&gt;. As of December 31, 2024, &lt;span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3QlD0iFgDFe" title="Common stock available for future issuance"&gt;36,174&lt;/span&gt; shares of common stock were available
for issuance under the 2021 Plan. &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember_zhNqzL3YEW72" title="Share based compensation arrangement by share based payment award, description"&gt;The number of shares of common stock available for issuance under the 2021 Plan will automatically
increase on January 1st of each year until the expiration of the 2021 Plan, in an amount equal to 5% percent of the total number of shares
of our common stock outstanding on December 31st of the preceding calendar year, on a fully diluted basis, unless the board of directors
takes action prior thereto to provide that there will not be an increase in the share reserve for such year or that the increase in the
share reserve for such year will be of a lesser number of shares of common stock than would otherwise occur.&lt;/span&gt; The shares of common stock
underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price
or tax withholding, repurchased or are otherwise terminated by the Company under the 2021 Plan will be added back to the shares of common
stock available for issuance under the 2021 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company recorded stock-based compensation expense of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember_zWbA9kYbz9kf" title="Share based compensation"&gt;995,484&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember_zSBePW0UJd87" title="Share based compensation"&gt;812,670&lt;/span&gt; during the years ended December 31, 2024 and 2023, relating
to options issued. As of December 31, 2024 and 2023, there was $&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember_zfAIpyJm2Ey3" title="Unrecognized share based costs"&gt;343,612&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember_zaRjXj7ycSM5" title="Unrecognized share based costs"&gt;1,278,981&lt;/span&gt; of unrecognized compensation cost related to nonvested
share-based compensation arrangements granted under the 2021 Plan, which is expected to be recognized over the next one to four years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zUSXUJf9MBOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
summary of option activity under the Plan during the years ended December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zg1NYTVbQ345" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Summary
of Option Activity&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual
    Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zVHaI1IhkDZ" style="width: 13%; font-weight: bold; text-align: right" title="Number of Shares Common stock options, outstanding at beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,588&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zONp7kZbA4Wd" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,651&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zVJuf3jCjvA4" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;326.76&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zcPH1RV5cRu4" title="Weighted Average Remaining Contractual Term, Grants"&gt;9.34&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zf61nf1R0427" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeitures or expirations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zIp9RNeFYvW2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeitures or expirations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,418&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zEVuTgMC8MJc" style="text-align: right" title="Weighted Average Exercise Price, Forfeitures and expirations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;618.60&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zJC9zM7bcpM4" style="text-align: right" title="Number of Shares Common stock options, outstanding at beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,821&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zL1AcLj0NzIa" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;733.68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_ztuZ4Lwn7O1a" title="Weighted Average Remaining Contractual Life (Years) Outstanding"&gt;8.55&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zwk9vbXQFWPb" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;89,032&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zhBBAYHIvs43" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zbLhxZVlBps6" title="Weighted Average Remaining Contractual Term, Grants"&gt;9.42&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zM8dki8mRjW6" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1144"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeitures or expirations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zWglAjDjAhm9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeitures or expirations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,447&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zXV1PzxWHytb" style="text-align: right" title="Weighted Average Exercise Price, Forfeitures and expirations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;757.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zid0MhOOJrXb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Common stock options, outstanding at ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;89,406&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_z64B9degM4R6" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.81&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zfCUYSjGCLk5" title="Weighted Average Remaining Contractual Life (Years) Outstanding"&gt;9.41&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected
    to vest at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_z1Vrmb9odtW2" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, Vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;89,406&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_z5pqTKRML0gg" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,156&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zPpoQcNGPdMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_gL3SOSBPASOVA-RPNHYI_z7hngl6Rpda7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zTtvwH6xnvm7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Fair Value Assumption&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaIimqClLeRi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTMIKdKG5G3d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_zWdthwwj6Kjg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.240&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.749&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEfy8swBTwyd" title="Expected term (in years)"&gt;5.43&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za6tJXl5TTKd" title="Expected term (in years)"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_zp8FHbPOESxe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_zWbJJY5S037i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zElwP1R1s656" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s stock options issued qualify for equity accounting treatment under ASC 718, &lt;i&gt;Compensation- Stock Compensation&lt;/i&gt;,
and are measured at fair value as of their grant date accordingly. The fair value of the options were estimated using a Black-Scholes
model. The assumptions that the Company used to estimate the grant-date fair value of stock options granted to employees and directors
were as follows, shown on a weighted average basis for the respective years ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_C0A_gL3SOSBPASOVA-RPNHYI_zxFaviBuuTZb"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C03_gL3SOSBPASOVA-RPNHYI_zeUZIXZff3ka"&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_303_134_zPjiuwHJLjm6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Fair Value Assumption (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zzNFB0XGqMr1" title="Risk-free interest rate"&gt;4.240&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zHbCN0HQ8IW" title="Risk-free interest rate"&gt;3.749&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z155CYRWux49" title="Expected term (in years)"&gt;5.43&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zsSf2SKMqmu1" title="Expected term (in years)"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zFNjdxUcSI8b" title="Expected volatility"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zpRIC25Miyg6" title="Expected volatility"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zs4ZNGupaDPh" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zSWsaTsuvTNa" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_C00_gL3SOSBPASOVA-RPNHYI_zGudwHPvNuQ3"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Risk-Free
Interest Rate&lt;/i&gt;: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity
of U.S. Treasury securities with similar maturities as of the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Expected
Term:&lt;/i&gt; The expected term represents the period that the options granted are expected to be outstanding and is determined using the
simplified method (based on the mid-point between the vesting dates and the end of the contractual term.)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Expected
Volatility&lt;/i&gt;: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology
and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient
trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information
regarding volatility of its own stock price becomes available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Expected
Dividend Yield&lt;/i&gt;: The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected
dividend yield was zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
grant-date fair value of options granted during the year ended December 31, 2024 ranged from $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zYiFZ0aQ095d" title="Grant date fair value"&gt;4.00&lt;/span&gt; to $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z7ire8ha3vzc" title="Grant date fair value"&gt;14.00&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zLKNvQAP4Nyk" title="Grant date fair value"&gt;153.96&lt;/span&gt; to $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zr1knX8KiV63" title="Grant date fair value"&gt;366.84&lt;/span&gt; for
options granted during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair
value of the Company&#x2019;s common stock. Because there were no stock options with exercise prices lower than the fair value of the
Company&#x2019;s common stock, the aggregate intrinsic value is &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_dc_c20241231_ziKjqUYxEvKl" title="Aggregate intrinsic value"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_dc_c20231231_zrYHlEXE08C4" title="Aggregate intrinsic value"&gt;zero&lt;/span&gt;&lt;/span&gt; as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-05-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001100"
      unitRef="Shares">104167</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001102"
      unitRef="Shares">125577</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001104"
      unitRef="Shares">36174</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember"
      id="Fact001106">The number of shares of common stock available for issuance under the 2021 Plan will automatically
increase on January 1st of each year until the expiration of the 2021 Plan, in an amount equal to 5% percent of the total number of shares
of our common stock outstanding on December 31st of the preceding calendar year, on a fully diluted basis, unless the board of directors
takes action prior thereto to provide that there will not be an increase in the share reserve for such year or that the increase in the
share reserve for such year will be of a lesser number of shares of common stock than would otherwise occur.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember"
      decimals="0"
      id="Fact001108"
      unitRef="USD">995484</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember"
      decimals="0"
      id="Fact001110"
      unitRef="USD">812670</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember"
      decimals="0"
      id="Fact001112"
      unitRef="USD">343612</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember"
      decimals="0"
      id="Fact001114"
      unitRef="USD">1278981</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001116">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zUSXUJf9MBOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
summary of option activity under the Plan during the years ended December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zg1NYTVbQ345" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Summary
of Option Activity&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual
    Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zVHaI1IhkDZ" style="width: 13%; font-weight: bold; text-align: right" title="Number of Shares Common stock options, outstanding at beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,588&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zONp7kZbA4Wd" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,651&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zVJuf3jCjvA4" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;326.76&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zcPH1RV5cRu4" title="Weighted Average Remaining Contractual Term, Grants"&gt;9.34&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zf61nf1R0427" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeitures or expirations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zIp9RNeFYvW2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeitures or expirations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,418&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zEVuTgMC8MJc" style="text-align: right" title="Weighted Average Exercise Price, Forfeitures and expirations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;618.60&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zJC9zM7bcpM4" style="text-align: right" title="Number of Shares Common stock options, outstanding at beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,821&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zL1AcLj0NzIa" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;733.68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_ztuZ4Lwn7O1a" title="Weighted Average Remaining Contractual Life (Years) Outstanding"&gt;8.55&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zwk9vbXQFWPb" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;89,032&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zhBBAYHIvs43" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zbLhxZVlBps6" title="Weighted Average Remaining Contractual Term, Grants"&gt;9.42&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zM8dki8mRjW6" style="text-align: right" title="Number of Shares, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1144"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeitures or expirations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zWglAjDjAhm9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeitures or expirations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,447&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zXV1PzxWHytb" style="text-align: right" title="Weighted Average Exercise Price, Forfeitures and expirations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;757.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zid0MhOOJrXb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Common stock options, outstanding at ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;89,406&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_z64B9degM4R6" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.81&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_zfCUYSjGCLk5" title="Weighted Average Remaining Contractual Life (Years) Outstanding"&gt;9.41&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected
    to vest at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_z1Vrmb9odtW2" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, Vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;89,406&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanPlanMember_z5pqTKRML0gg" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,156&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001118"
      unitRef="Shares">3588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001120"
      unitRef="Shares">2651</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001122"
      unitRef="USDPShares">326.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <CING:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      id="Fact001124">P9Y4M2D</CING:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2023-01-012023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001128"
      unitRef="Shares">1418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001130"
      unitRef="USDPShares">618.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001132"
      unitRef="Shares">4821</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001134"
      unitRef="USDPShares">733.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      id="Fact001136">P8Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001138"
      unitRef="Shares">89032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001140"
      unitRef="USDPShares">13.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <CING:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      id="Fact001142">P9Y5M1D</CING:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001146"
      unitRef="Shares">4447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001148"
      unitRef="USDPShares">757.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001150"
      unitRef="Shares">89406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001152"
      unitRef="USDPShares">14.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      id="Fact001154">P9Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001156"
      unitRef="Shares">89406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanPlanMember"
      decimals="INF"
      id="Fact001158"
      unitRef="Shares">48156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001163">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_gL3SOSBPASOVA-RPNHYI_z7hngl6Rpda7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zTtvwH6xnvm7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Fair Value Assumption&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaIimqClLeRi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTMIKdKG5G3d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_zWdthwwj6Kjg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.240&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.749&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEfy8swBTwyd" title="Expected term (in years)"&gt;5.43&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za6tJXl5TTKd" title="Expected term (in years)"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_zp8FHbPOESxe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_zWbJJY5S037i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_303_134_zPjiuwHJLjm6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Fair Value Assumption (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zzNFB0XGqMr1" title="Risk-free interest rate"&gt;4.240&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zHbCN0HQ8IW" title="Risk-free interest rate"&gt;3.749&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z155CYRWux49" title="Expected term (in years)"&gt;5.43&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zsSf2SKMqmu1" title="Expected term (in years)"&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zFNjdxUcSI8b" title="Expected volatility"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zpRIC25Miyg6" title="Expected volatility"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zs4ZNGupaDPh" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zSWsaTsuvTNa" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001165"
      unitRef="Pure">0.04240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001166"
      unitRef="Pure">0.03749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact001168">P5Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact001170">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001172"
      unitRef="Pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001173"
      unitRef="Pure">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001175"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001176"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact001178"
      unitRef="Pure">0.04240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact001180"
      unitRef="Pure">0.03749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_custom_EmployeesAndDirectorsMember"
      id="Fact001182">P5Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndDirectorsMember"
      id="Fact001184">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact001186"
      unitRef="Pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact001188"
      unitRef="Pure">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact001190"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact001192"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001194"
      unitRef="USDPShares">4.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001196"
      unitRef="USDPShares">14.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001198"
      unitRef="USDPShares">153.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001200"
      unitRef="USDPShares">366.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001202"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001204"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001206">&lt;p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zF3YHZQ5pbec" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(13)
&lt;span id="xdx_822_zhgN0ILY1ibi"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cingulate
Inc. is taxed as a C corporation under the Internal Revenue Code. Cingulate Inc. records deferred income taxes to reflect the impact
of temporary differences between the recorded amounts of assets and liabilities for financial reporting purposes and such amounts as
measured by tax laws and regulations. CTx is a wholly-owned disregarded entity of Cingulate Inc., and all of the activity for CTx, along
with its wholly-owned subsidiary Cingulate Works Inc., is included in the calculation of the current and deferred tax assets and liabilities
for Cingulate Inc. No deferred income tax benefit or expense was recorded as of December 31, 2024 or December 31, 2023, for federal or
state income taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzkI7J4KBEpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
tax expense differed from the expected expense computed by applying U.S. Federal income tax rate for the respective years ended as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zYWII1YXUt7e" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_zYoP00pZXvW" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zPc6Fs9hiwDc" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzqB9_zRDr3sk5ehF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal income tax benefit at statutory
    rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,264,659&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,936,484&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzqB9_zs9P03lyyZ57" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(541,359&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,299,941&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationPermanentDifference_maITEBzqB9_zMLak4vFcSj5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,582&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,239&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzqB9_zNMlRFDQFqxh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,802,119&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,050,437&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeTaxReconciliationResearchAndDevelopmentTaxCrediitPriorPeriod_maITEBzqB9_zAhwKRehDaE5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development tax credit- prior
    period&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(972,372&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(775,982&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzqB9_zWdhdELCqn6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(37,311&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(56,269&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzqB9_z5TemKIF82Db" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1228"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zRwGutLW7Alh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Evaluating
the need for, and amount of, a valuation allowance for deferred tax assets often requires significant judgment and extensive analysis
of all available evidence on a jurisdiction-by-jurisdiction basis. Such judgments require the Company to interpret existing tax law and
other published guidance as applied to its circumstances. As part of this assessment, the Company considers both positive and negative
evidence about its profitability and tax situation. A valuation allowance is provided if, based on available evidence, it is more likely
than not that all or some portion of a deferred tax asset will not be realized. The Company determined that it was more likely than not
that it would not realize its deferred tax assets, based on historical levels of income and future forecasts of taxable income, among
other items. The Company recorded a valuation allowance of its net deferred tax assets totaling $&lt;span id="xdx_90D_ecustom--DeferredTaxAssetNetCurrent_iI_c20241231_z8KEMRiTNIkg" title="Net deferred tax assets"&gt;17,405,569 &lt;/span&gt;and $&lt;span id="xdx_90B_ecustom--DeferredTaxAssetNetCurrent_iI_c20231231_zOgRuuESs3fd" title="Net deferred tax assets"&gt;12,631,033&lt;/span&gt;, respectively,
at December 31, 2024 and 2023, which was recorded as a component of income tax expense on the accompanying consolidated statements of
operations and other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company files income tax returns in the U.S. federal and various state jurisdictions. The Company is not subject to U.S. federal and
state income tax examinations by tax authorities for years before 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company follows the provisions of ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;, to evaluate uncertain tax positions. This topic prescribes a recognition
threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be
taken in a tax return. The Company has not identified any material uncertain tax positions requiring recognition in the consolidated
financial statements as of December 31, 2024 or December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUnDZsbcqeqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zkpKRhueHc33" style="display: none"&gt;Schedule of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_zuwENowPISd4" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zlWezQ26xKuk" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsInResearchAndDevelopmentCostsCurrent_iI_maDTAGzvyH_zfjrGZ60YCIl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; width: 60%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,662,662&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,257,027&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsOtherCurrent_iI_maDTAGzvyH_zbZnCqIBmTuf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;443&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,870&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzvyH_zaZBscXtt3y5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    operating losses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,314,876&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,515,232&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzvyH_zh3AKhPhYx2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,269,254&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,051,553&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsUnvestedStockOptionsNonCurrent_iI_maDTAGzvyH_zrf4dNWyTKOi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested
    stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;693,193&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;447,355&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsInResearchAndDevelopmentTaxCredit_iI_maDTAGzvyH_zglKFqQNZtV3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,728,495&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;756,123&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGzvyH_zSDT7xVw2FU1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;146,433&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;110,700&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxAssetsRightofuseAssets_iI_maDTAGzvyH_zNnSE21UHEul" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Right-of-use
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,430&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,706&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzvyH_maDTANzoyP_zrYg2TF0meMb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,797,203&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,194,566&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzoyP_zqQHxYhMxI66" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(17,433,152&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(12,631,033&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzoyP_maDTALNzzdm_zn3HOCfEP1X2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.5in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred income tax asset&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;391,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;563,533&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di_maDITLzK1U_zmkAYWuEsQNi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
    and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(391,634&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(563,533&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzK1U_msDTALNzzdm_zPa0FrLLJo98" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(391,634&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(563,533&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzzdm_zhFHLnXg2Oac" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred tax asset (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1276"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1277"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zhD2tqGGhjBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001208">&lt;p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzkI7J4KBEpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income
tax expense differed from the expected expense computed by applying U.S. Federal income tax rate for the respective years ended as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zYWII1YXUt7e" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_zYoP00pZXvW" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zPc6Fs9hiwDc" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzqB9_zRDr3sk5ehF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal income tax benefit at statutory
    rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,264,659&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,936,484&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzqB9_zs9P03lyyZ57" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(541,359&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,299,941&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationPermanentDifference_maITEBzqB9_zMLak4vFcSj5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,582&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,239&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzqB9_zNMlRFDQFqxh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,802,119&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,050,437&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeTaxReconciliationResearchAndDevelopmentTaxCrediitPriorPeriod_maITEBzqB9_zAhwKRehDaE5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development tax credit- prior
    period&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(972,372&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(775,982&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzqB9_zWdhdELCqn6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(37,311&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(56,269&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzqB9_z5TemKIF82Db" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1228"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001210"
      unitRef="USD">-3264659</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001211"
      unitRef="USD">-4936484</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001213"
      unitRef="USD">-541359</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001214"
      unitRef="USD">-1299941</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <CING:IncomeTaxReconciliationPermanentDifference
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001216"
      unitRef="USD">13582</CING:IncomeTaxReconciliationPermanentDifference>
    <CING:IncomeTaxReconciliationPermanentDifference
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001217"
      unitRef="USD">18239</CING:IncomeTaxReconciliationPermanentDifference>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001219"
      unitRef="USD">4802119</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001220"
      unitRef="USD">7050437</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <CING:IncomeTaxReconciliationResearchAndDevelopmentTaxCrediitPriorPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001222"
      unitRef="USD">-972372</CING:IncomeTaxReconciliationResearchAndDevelopmentTaxCrediitPriorPeriod>
    <CING:IncomeTaxReconciliationResearchAndDevelopmentTaxCrediitPriorPeriod
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001223"
      unitRef="USD">-775982</CING:IncomeTaxReconciliationResearchAndDevelopmentTaxCrediitPriorPeriod>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001225"
      unitRef="USD">-37311</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001226"
      unitRef="USD">-56269</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <CING:DeferredTaxAssetNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001231"
      unitRef="USD">17405569</CING:DeferredTaxAssetNetCurrent>
    <CING:DeferredTaxAssetNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001233"
      unitRef="USD">12631033</CING:DeferredTaxAssetNetCurrent>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001235">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUnDZsbcqeqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zkpKRhueHc33" style="display: none"&gt;Schedule of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_zuwENowPISd4" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zlWezQ26xKuk" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsInResearchAndDevelopmentCostsCurrent_iI_maDTAGzvyH_zfjrGZ60YCIl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; width: 60%; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,662,662&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,257,027&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsOtherCurrent_iI_maDTAGzvyH_zbZnCqIBmTuf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;443&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,870&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzvyH_zaZBscXtt3y5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    operating losses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,314,876&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,515,232&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzvyH_zh3AKhPhYx2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,269,254&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,051,553&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsUnvestedStockOptionsNonCurrent_iI_maDTAGzvyH_zrf4dNWyTKOi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested
    stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;693,193&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;447,355&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsInResearchAndDevelopmentTaxCredit_iI_maDTAGzvyH_zglKFqQNZtV3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,728,495&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;756,123&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGzvyH_zSDT7xVw2FU1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;146,433&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;110,700&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxAssetsRightofuseAssets_iI_maDTAGzvyH_zNnSE21UHEul" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Right-of-use
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,430&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,706&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzvyH_maDTANzoyP_zrYg2TF0meMb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,797,203&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,194,566&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzoyP_zqQHxYhMxI66" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(17,433,152&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(12,631,033&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzoyP_maDTALNzzdm_zn3HOCfEP1X2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.5in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred income tax asset&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;391,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;563,533&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di_maDITLzK1U_zmkAYWuEsQNi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
    and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(391,634&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(563,533&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzK1U_msDTALNzzdm_zPa0FrLLJo98" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(391,634&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(563,533&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzzdm_zhFHLnXg2Oac" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred tax asset (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1276"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1277"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <CING:DeferredTaxAssetsInResearchAndDevelopmentCostsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001237"
      unitRef="USD">1662662</CING:DeferredTaxAssetsInResearchAndDevelopmentCostsCurrent>
    <CING:DeferredTaxAssetsInResearchAndDevelopmentCostsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001238"
      unitRef="USD">1257027</CING:DeferredTaxAssetsInResearchAndDevelopmentCostsCurrent>
    <CING:DeferredTaxAssetsOtherCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001240"
      unitRef="USD">443</CING:DeferredTaxAssetsOtherCurrent>
    <CING:DeferredTaxAssetsOtherCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001241"
      unitRef="USD">17870</CING:DeferredTaxAssetsOtherCurrent>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001243"
      unitRef="USD">9314876</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001244"
      unitRef="USD">6515232</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001246"
      unitRef="USD">4269254</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001247"
      unitRef="USD">4051553</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <CING:DeferredTaxAssetsUnvestedStockOptionsNonCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001249"
      unitRef="USD">693193</CING:DeferredTaxAssetsUnvestedStockOptionsNonCurrent>
    <CING:DeferredTaxAssetsUnvestedStockOptionsNonCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001250"
      unitRef="USD">447355</CING:DeferredTaxAssetsUnvestedStockOptionsNonCurrent>
    <CING:DeferredTaxAssetsInResearchAndDevelopmentTaxCredit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001252"
      unitRef="USD">1728495</CING:DeferredTaxAssetsInResearchAndDevelopmentTaxCredit>
    <CING:DeferredTaxAssetsInResearchAndDevelopmentTaxCredit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001253"
      unitRef="USD">756123</CING:DeferredTaxAssetsInResearchAndDevelopmentTaxCredit>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001255"
      unitRef="USD">146433</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001256"
      unitRef="USD">110700</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <CING:DeferredTaxAssetsRightofuseAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001258"
      unitRef="USD">9430</CING:DeferredTaxAssetsRightofuseAssets>
    <CING:DeferredTaxAssetsRightofuseAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001259"
      unitRef="USD">38706</CING:DeferredTaxAssetsRightofuseAssets>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001261"
      unitRef="USD">17797203</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001262"
      unitRef="USD">13194566</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001264"
      unitRef="USD">17433152</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001265"
      unitRef="USD">12631033</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001267"
      unitRef="USD">391634</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001268"
      unitRef="USD">563533</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001270"
      unitRef="USD">391634</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001271"
      unitRef="USD">563533</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001273"
      unitRef="USD">391634</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001274"
      unitRef="USD">563533</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001279">&lt;p id="xdx_80D_eus-gaap--LesseeOperatingLeasesTextBlock_zlAQ9yDWpHji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(14)
&lt;span id="xdx_825_zKgaOT7QrYPd"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
June 2019, the Company executed a lease, which included expansion and renovation of previously leased space for its headquarters in Kansas
City, Kansas. The lease has a &lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20190630__us-gaap--LeaseContractualTermAxis__custom--KansasCityOfficeMember_zmHAKek9Ja72" title="Lease term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1281"&gt;five&lt;/span&gt;&lt;/span&gt;-year term that commenced on May 1, 2020, the date of receipt of a Certificate of Occupancy for the
expanded and renovated space. Under this lease, total rent ranges from $&lt;span id="xdx_904_eus-gaap--PaymentsForRent_c20190601__20190630__us-gaap--LeaseContractualTermAxis__custom--KansasCityOfficeMember__srt--RangeAxis__srt--MinimumMember_zWVjAO3aAI8f" title="Rent expense"&gt;30,453&lt;/span&gt; to $&lt;span id="xdx_900_eus-gaap--PaymentsForRent_c20190601__20190630__us-gaap--LeaseContractualTermAxis__custom--KansasCityOfficeMember__srt--RangeAxis__srt--MaximumMember_zUKLfuRLwC13" title="Rent expense per month"&gt;33,145&lt;/span&gt; per month over the lease term. This lease provided
for a lease incentive by the lessor of tenant improvements totaling $&lt;span id="xdx_90C_eus-gaap--TenantImprovements_iI_c20190630__us-gaap--LeaseContractualTermAxis__custom--KansasCityOfficeMember_z6JbfDoKp6L2" title="Lease incentive by lessor of tenant improvements"&gt;201,600&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
January 2021, the Company executed a three-year lease for office space in New Jersey from a related party, as further described in Note
17. The base rent for this lease, which expired on December 31, 2023, was $&lt;span id="xdx_909_eus-gaap--PaymentsForRent_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--OfficeFacilitiesSpaceMember_zh5fZZjYkZf5" title="Payments for rent"&gt;3,000&lt;/span&gt; per month.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20240101__20241231_zLj77GnUKHH1" title="Lease description"&gt;In
April 2020, the Company entered into a 60-month lease agreement for office furniture under a lease classified as a financing lease as
title of the furniture transfers to the Company at the end of the lease term. Monthly lease payments are $&lt;span id="xdx_90B_eus-gaap--PaymentsForRent_c20200401__20200430_zgfrZ0vW33lh" title="Rent expense per month"&gt;1,491&lt;/span&gt;. The leased furniture
is amortized on a straight-line basis over 7 years. The imputed interest rate relating to the lease obligation is &lt;span id="xdx_901_ecustom--PercentageOfImputedInterestRateOfLeaseObligation_pid_dp_uPure_c20200401__20200430_zMyTnw2ZVkJj" title="Percentage of imputed interest rate, lease obligation"&gt;6.12%&lt;/span&gt; and the maturity
date is March 2025.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zKKWllFQPtjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
components of lease cost for the years ended December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_z29TUnfRdWsf" style="display: none"&gt;Summary of Components of Lease Cost&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zJQoSRBrXk81" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_z9Xttwkn6OJa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzXzT_zyp0m6uVxybh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;302,786&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;338,787&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_maFLCzB8j_zQ2JmmoBMINg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization of right-of-use
    assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,990&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,990&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseInterestExpense_maFLCzB8j_zdM8FPdLVgK7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest
    on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;842&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,853&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinanceLeaseCost_iT_maLCzXzT_mtFLCzB8j_zzHauOHOroo6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,832&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,843&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LeaseCost_iT_mtLCzXzT_zmDqvWtTJMVh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;314,618&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;351,630&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_z7CeadFIFCC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfLeaseAssetsAndLiabilitiesRecordedInConsolidatedBalanceSheetsTableTextBlock_zq3p5Pk7qmsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amounts reported
in the consolidated balance sheets as of December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_8BB_zBrS9YdmUG71" style="display: none"&gt;Summary of Lease Reported in Consolidated Balance Sheets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zrFWzR3GRhHj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_zQpupBhbEySa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating Leases:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zZyAx91x2Ki" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease
    right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99,011&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;366,877&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzGr4_znoABMnWTj6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease liability,
    current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,662&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;358,085&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzGr4_z6YzhekCbOSj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    lease liabilities, net of current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,663&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzGr4_z7iZc6fjBelb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 30pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,662&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;488,748&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_iI_maPPAENzhp4_ztTWPDZ4VxWc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;76,928&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;76,928&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_iNI_di_msPPAENzhp4_zlz1yvYs0e6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated
    amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(75,759&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(60,373&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_iTI_mtPPAENzhp4_zaYt1MXHukX9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 40pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
    and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,169&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,555&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current installments of obligations under&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityCurrent_iI_maFLLzrS1_zjmOiybirH9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance lease liability,
    current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,430&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,057&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_maFLLzrS1_ztHBIBxi0Cyb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance
    lease liability, net of current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1340"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,436&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iTI_mtFLLzrS1_z80Vk4u5hyye" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 30pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,430&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,493&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zU1DBdOqOVVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zeadNkTkU3M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
information relating to leases as of December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zEko8f8iMpYj" style="display: none"&gt;Summary of Other Information Relating to Leases&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Supplemental cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reductions to ROU assets resulting from reductions
    to lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--OperatingLeasesReductionsToRightOfUseAssetsLeaseObligations_c20240101__20241231_zsqXegapSHf9" style="width: 16%; text-align: right" title="Reductions to ROU assets resulting from reductions to lease obligations: Operating leases"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;267,886&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OperatingLeasesReductionsToRightOfUseAssetsLeaseObligations_c20230101__20231231_zHcRIC03wfE8" style="width: 16%; text-align: right" title="Reductions to ROU assets resulting from reductions to lease obligations: Operating leases"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;263,741&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--FinanceLeasesReductionsToRightOfUseAssetsLeaseObligations_c20240101__20241231_zbh2EjpfzPI7" style="text-align: right" title="Reductions to ROU assets resulting from reductions to lease obligations: Finance leases"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,990&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FinanceLeasesReductionsToRightOfUseAssetsLeaseObligations_c20230101__20231231_zHM60knzMZxf" style="text-align: right" title="Reductions to ROU assets resulting from reductions to lease obligations: Finance leases"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,990&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20241231_zg2iBm9U22Zb" title="Weighted average remaining lease term: Operating leases"&gt;5&lt;/span&gt;
                                            months &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20231231_zuUqCpU785lj" title="Weighted average remaining lease term: Operating leases"&gt;17&lt;/span&gt;
                                            months &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_905_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20241231_zIgNfGx5rwQk" title="Weighted average remaining lease term: Finance leases"&gt;3&lt;/span&gt;
                                            months &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_90C_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20231231_zaDTZxV8xqQ5" title="Weighted average remaining lease term: Finance leases"&gt;15&lt;/span&gt;
                                            months &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zuwtoAYjeSX2" title="Weighted average discount rate: operating leases"&gt;11.76&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zmS0K3exxlw2" title="Weighted average discount rate: operating leases"&gt;11.76&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zh6eBwFdJQo" title="Weighted average discount rate: Finance leases"&gt;6.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_z0m9UKNXPGd7" title="Weighted average discount rate: Finance leases"&gt;6.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z2iexjPs4nO" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_zqKWv7s53afj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Maturities
of lease liabilities under noncancellable leases as of December 31, 2024 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_znD799tqVH1b" style="display: none"&gt;Summary of Maturity of Lease Liabilities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maOLAFL1_c20241231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zVidY5d6MPO2" style="width: 16%; text-align: right" title="2025"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;132,580&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maOLAFL1_c20231231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zXyAGnJe4XZk" style="width: 16%; text-align: right" title="2025"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,475&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maOLAFL1_c20241231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zSBwMbwdoor3" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1378"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maOLAFL1_c20231231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_z92xwxr6xH15" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1380"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLAFL1_c20241231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zcyaltZLsX1e" style="text-align: right" title="Total undiscounted lease payments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;132,580&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLAFL1_c20231231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zgMv6R8yrjlk" style="text-align: right" title="Total undiscounted lease payments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,475&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less
    imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20241231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zHEzSnDQqMQh" style="border-bottom: Black 1pt solid; text-align: right" title="Less imputed interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,918&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20231231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zbXQ2Rc2MU8f" style="border-bottom: Black 1pt solid; text-align: right" title="Less imputed interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_c20241231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zIa0YfbmYGa4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,662&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeaseLiability_iI_c20231231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zQhpC25KkRE2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,430&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zJNu1mnagcoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:PaymentsForRent
      contextRef="From2019-06-012019-06-30_custom_KansasCityOfficeMember_srt_MinimumMember"
      decimals="0"
      id="Fact001283"
      unitRef="USD">30453</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2019-06-012019-06-30_custom_KansasCityOfficeMember_srt_MaximumMember"
      decimals="0"
      id="Fact001285"
      unitRef="USD">33145</us-gaap:PaymentsForRent>
    <us-gaap:TenantImprovements
      contextRef="AsOf2019-06-30_custom_KansasCityOfficeMember"
      decimals="0"
      id="Fact001287"
      unitRef="USD">201600</us-gaap:TenantImprovements>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-012023-12-31_custom_OfficeFacilitiesSpaceMember"
      decimals="0"
      id="Fact001289"
      unitRef="USD">3000</us-gaap:PaymentsForRent>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2024-01-01to2024-12-31" id="Fact001291">In
April 2020, the Company entered into a 60-month lease agreement for office furniture under a lease classified as a financing lease as
title of the furniture transfers to the Company at the end of the lease term. Monthly lease payments are $1,491. The leased furniture
is amortized on a straight-line basis over 7 years. The imputed interest rate relating to the lease obligation is 6.12% and the maturity
date is March 2025.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:PaymentsForRent
      contextRef="From2020-04-012020-04-30"
      decimals="0"
      id="Fact001293"
      unitRef="USD">1491</us-gaap:PaymentsForRent>
    <CING:PercentageOfImputedInterestRateOfLeaseObligation
      contextRef="From2020-04-012020-04-30"
      decimals="INF"
      id="Fact001295"
      unitRef="Pure">0.0612</CING:PercentageOfImputedInterestRateOfLeaseObligation>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001297">&lt;p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zKKWllFQPtjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
components of lease cost for the years ended December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_z29TUnfRdWsf" style="display: none"&gt;Summary of Components of Lease Cost&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zJQoSRBrXk81" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_z9Xttwkn6OJa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzXzT_zyp0m6uVxybh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;302,786&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;338,787&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_maFLCzB8j_zQ2JmmoBMINg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization of right-of-use
    assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,990&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,990&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseInterestExpense_maFLCzB8j_zdM8FPdLVgK7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest
    on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;842&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,853&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinanceLeaseCost_iT_maLCzXzT_mtFLCzB8j_zzHauOHOroo6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,832&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,843&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LeaseCost_iT_mtLCzXzT_zmDqvWtTJMVh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;314,618&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;351,630&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001299"
      unitRef="USD">302786</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001300"
      unitRef="USD">338787</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001302"
      unitRef="USD">10990</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001303"
      unitRef="USD">10990</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001305"
      unitRef="USD">842</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001306"
      unitRef="USD">1853</us-gaap:FinanceLeaseInterestExpense>
    <CING:FinanceLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001308"
      unitRef="USD">11832</CING:FinanceLeaseCost>
    <CING:FinanceLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001309"
      unitRef="USD">12843</CING:FinanceLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001311"
      unitRef="USD">314618</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001312"
      unitRef="USD">351630</us-gaap:LeaseCost>
    <CING:ScheduleOfLeaseAssetsAndLiabilitiesRecordedInConsolidatedBalanceSheetsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001314">&lt;p id="xdx_89C_ecustom--ScheduleOfLeaseAssetsAndLiabilitiesRecordedInConsolidatedBalanceSheetsTableTextBlock_zq3p5Pk7qmsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amounts reported
in the consolidated balance sheets as of December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_8BB_zBrS9YdmUG71" style="display: none"&gt;Summary of Lease Reported in Consolidated Balance Sheets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zrFWzR3GRhHj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_zQpupBhbEySa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating Leases:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zZyAx91x2Ki" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease
    right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99,011&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;366,877&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzGr4_znoABMnWTj6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease liability,
    current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,662&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;358,085&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzGr4_z6YzhekCbOSj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    lease liabilities, net of current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,663&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzGr4_z7iZc6fjBelb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 30pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,662&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;488,748&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_iI_maPPAENzhp4_ztTWPDZ4VxWc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;76,928&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;76,928&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_iNI_di_msPPAENzhp4_zlz1yvYs0e6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated
    amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(75,759&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(60,373&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_iTI_mtPPAENzhp4_zaYt1MXHukX9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 40pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
    and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,169&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,555&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current installments of obligations under&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityCurrent_iI_maFLLzrS1_zjmOiybirH9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance lease liability,
    current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,430&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,057&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_maFLLzrS1_ztHBIBxi0Cyb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance
    lease liability, net of current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1340"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,436&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iTI_mtFLLzrS1_z80Vk4u5hyye" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 30pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,430&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,493&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CING:ScheduleOfLeaseAssetsAndLiabilitiesRecordedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001316"
      unitRef="USD">99011</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001317"
      unitRef="USD">366877</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001319"
      unitRef="USD">130662</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001320"
      unitRef="USD">358085</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001323"
      unitRef="USD">130663</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001325"
      unitRef="USD">130662</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001326"
      unitRef="USD">488748</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001328"
      unitRef="USD">76928</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001329"
      unitRef="USD">76928</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001331"
      unitRef="USD">75759</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001332"
      unitRef="USD">60373</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001334"
      unitRef="USD">1169</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001335"
      unitRef="USD">16555</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001337"
      unitRef="USD">4430</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001338"
      unitRef="USD">17057</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001341"
      unitRef="USD">4436</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001343"
      unitRef="USD">4430</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001344"
      unitRef="USD">21493</us-gaap:FinanceLeaseLiability>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001346">&lt;p id="xdx_89D_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zeadNkTkU3M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
information relating to leases as of December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zEko8f8iMpYj" style="display: none"&gt;Summary of Other Information Relating to Leases&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Supplemental cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reductions to ROU assets resulting from reductions
    to lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--OperatingLeasesReductionsToRightOfUseAssetsLeaseObligations_c20240101__20241231_zsqXegapSHf9" style="width: 16%; text-align: right" title="Reductions to ROU assets resulting from reductions to lease obligations: Operating leases"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;267,886&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OperatingLeasesReductionsToRightOfUseAssetsLeaseObligations_c20230101__20231231_zHcRIC03wfE8" style="width: 16%; text-align: right" title="Reductions to ROU assets resulting from reductions to lease obligations: Operating leases"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;263,741&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--FinanceLeasesReductionsToRightOfUseAssetsLeaseObligations_c20240101__20241231_zbh2EjpfzPI7" style="text-align: right" title="Reductions to ROU assets resulting from reductions to lease obligations: Finance leases"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,990&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FinanceLeasesReductionsToRightOfUseAssetsLeaseObligations_c20230101__20231231_zHM60knzMZxf" style="text-align: right" title="Reductions to ROU assets resulting from reductions to lease obligations: Finance leases"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,990&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20241231_zg2iBm9U22Zb" title="Weighted average remaining lease term: Operating leases"&gt;5&lt;/span&gt;
                                            months &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20231231_zuUqCpU785lj" title="Weighted average remaining lease term: Operating leases"&gt;17&lt;/span&gt;
                                            months &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_905_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20241231_zIgNfGx5rwQk" title="Weighted average remaining lease term: Finance leases"&gt;3&lt;/span&gt;
                                            months &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_90C_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20231231_zaDTZxV8xqQ5" title="Weighted average remaining lease term: Finance leases"&gt;15&lt;/span&gt;
                                            months &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zuwtoAYjeSX2" title="Weighted average discount rate: operating leases"&gt;11.76&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zmS0K3exxlw2" title="Weighted average discount rate: operating leases"&gt;11.76&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zh6eBwFdJQo" title="Weighted average discount rate: Finance leases"&gt;6.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_z0m9UKNXPGd7" title="Weighted average discount rate: Finance leases"&gt;6.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <CING:OperatingLeasesReductionsToRightOfUseAssetsLeaseObligations
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001348"
      unitRef="USD">267886</CING:OperatingLeasesReductionsToRightOfUseAssetsLeaseObligations>
    <CING:OperatingLeasesReductionsToRightOfUseAssetsLeaseObligations
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001350"
      unitRef="USD">263741</CING:OperatingLeasesReductionsToRightOfUseAssetsLeaseObligations>
    <CING:FinanceLeasesReductionsToRightOfUseAssetsLeaseObligations
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001352"
      unitRef="USD">10990</CING:FinanceLeasesReductionsToRightOfUseAssetsLeaseObligations>
    <CING:FinanceLeasesReductionsToRightOfUseAssetsLeaseObligations
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001354"
      unitRef="USD">10990</CING:FinanceLeasesReductionsToRightOfUseAssetsLeaseObligations>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact001356">P5M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-12-31" id="Fact001358">P17M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact001360">P3M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-12-31" id="Fact001362">P15M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001364"
      unitRef="Pure">0.1176</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001366"
      unitRef="Pure">0.1176</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001368"
      unitRef="Pure">0.0612</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001370"
      unitRef="Pure">0.0612</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <CING:ScheduleOfOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001372">&lt;p id="xdx_89B_ecustom--ScheduleOfOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_zqKWv7s53afj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Maturities
of lease liabilities under noncancellable leases as of December 31, 2024 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_znD799tqVH1b" style="display: none"&gt;Summary of Maturity of Lease Liabilities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maOLAFL1_c20241231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zVidY5d6MPO2" style="width: 16%; text-align: right" title="2025"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;132,580&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maOLAFL1_c20231231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zXyAGnJe4XZk" style="width: 16%; text-align: right" title="2025"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,475&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maOLAFL1_c20241231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zSBwMbwdoor3" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1378"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maOLAFL1_c20231231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_z92xwxr6xH15" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1380"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLAFL1_c20241231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zcyaltZLsX1e" style="text-align: right" title="Total undiscounted lease payments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;132,580&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOLAFL1_c20231231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zgMv6R8yrjlk" style="text-align: right" title="Total undiscounted lease payments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,475&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 0pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less
    imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20241231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zHEzSnDQqMQh" style="border-bottom: Black 1pt solid; text-align: right" title="Less imputed interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,918&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20231231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zbXQ2Rc2MU8f" style="border-bottom: Black 1pt solid; text-align: right" title="Less imputed interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_c20241231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zIa0YfbmYGa4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,662&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeaseLiability_iI_c20231231__us-gaap--LeaseContractualTermAxis__custom--OperatingLeaseMember_zQhpC25KkRE2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,430&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CING:ScheduleOfOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-12-31_custom_OperatingLeaseMember"
      decimals="0"
      id="Fact001374"
      unitRef="USD">132580</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31_custom_OperatingLeaseMember"
      decimals="0"
      id="Fact001376"
      unitRef="USD">4475</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31_custom_OperatingLeaseMember"
      decimals="0"
      id="Fact001382"
      unitRef="USD">132580</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2023-12-31_custom_OperatingLeaseMember"
      decimals="0"
      id="Fact001384"
      unitRef="USD">4475</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31_custom_OperatingLeaseMember"
      decimals="0"
      id="Fact001386"
      unitRef="USD">1918</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2023-12-31_custom_OperatingLeaseMember"
      decimals="0"
      id="Fact001388"
      unitRef="USD">45</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31_custom_OperatingLeaseMember"
      decimals="0"
      id="Fact001390"
      unitRef="USD">130662</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31_custom_OperatingLeaseMember"
      decimals="0"
      id="Fact001392"
      unitRef="USD">4430</us-gaap:OperatingLeaseLiability>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001394">&lt;p id="xdx_801_eus-gaap--EarningsPerShareTextBlock_zoxBkLXyQWha" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(15)
&lt;span id="xdx_823_zXHRLB7fwIMf"&gt;Net Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of common shares
and pre-funded warrants outstanding during the period. The pre-funded warrants are included in the calculation of the weighted-average
number of shares outstanding because their exercise requires only nominal consideration for the delivery of shares. The following table
sets forth the computation of the basic and diluted net loss per share for years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zmPh0k04Cjn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zz30v9UpmNJ7" style="display: none"&gt;Schedule
of Net  Loss Per Share Basic and Diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20241231_z5uSEoUQnL46" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231_z0TL0EkHemab" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_zntKXPVz6mVe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,545,737&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23,534,947&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average common
    shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zpoYhuE5P6ia" title="Weighted average number of shares used in computing net loss per share of common stock, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zZ0UcPIm9dI3" title="Weighted average number of shares used in computing net loss per share of common stock, diluted"&gt;1,524,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_z65RH0AUyu99" title="Weighted average number of shares used in computing net loss per share of common stock, basic"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zzxJSskaa0uf" title="Weighted average number of shares used in computing net loss per share of common stock, diluted"&gt;75,435&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss per share,
    basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zC3j3fxBYLGi" title="Net loss per share of common stock, basic"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_z0ISW19Ck4Eg" title="Net loss per share of common stock, diluted"&gt;(10.20&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zbv3j1y66Ca7" title="Net loss per share of common stock, basic"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zaf50tMeU4Bj" title="Net loss per share of common stock, diluted"&gt;(311.99&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zkZcgMhKfCB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zd9fOLKSJFZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Potentially
dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zY4MRGeQVVY2" style="display: none"&gt;Schedule of Potentially Dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_zV10JSOHLKea" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zeILSlclRqT9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zdnHo0T96T39" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options issued under the
    2021 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;89,406&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,775&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zVRiwiOdXMG3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock purchase
    warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;833,684&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65,559&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zjmCn74DfEne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;923,090&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70,334&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zNcCUuBWj5El" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Antidilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;923,090&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;70,334&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AD_z23dJqyyRCui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001396">&lt;p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zmPh0k04Cjn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zz30v9UpmNJ7" style="display: none"&gt;Schedule
of Net  Loss Per Share Basic and Diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20241231_z5uSEoUQnL46" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231_z0TL0EkHemab" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_zntKXPVz6mVe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,545,737&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23,534,947&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average common
    shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zpoYhuE5P6ia" title="Weighted average number of shares used in computing net loss per share of common stock, basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zZ0UcPIm9dI3" title="Weighted average number of shares used in computing net loss per share of common stock, diluted"&gt;1,524,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_z65RH0AUyu99" title="Weighted average number of shares used in computing net loss per share of common stock, basic"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zzxJSskaa0uf" title="Weighted average number of shares used in computing net loss per share of common stock, diluted"&gt;75,435&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss per share,
    basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zC3j3fxBYLGi" title="Net loss per share of common stock, basic"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_z0ISW19Ck4Eg" title="Net loss per share of common stock, diluted"&gt;(10.20&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zbv3j1y66Ca7" title="Net loss per share of common stock, basic"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zaf50tMeU4Bj" title="Net loss per share of common stock, diluted"&gt;(311.99&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001398"
      unitRef="USD">-15545737</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001399"
      unitRef="USD">-23534947</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001401"
      unitRef="Shares">1524797</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001403"
      unitRef="Shares">1524797</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001405"
      unitRef="Shares">75435</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001407"
      unitRef="Shares">75435</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001409"
      unitRef="USDPShares">-10.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001411"
      unitRef="USDPShares">-10.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001413"
      unitRef="USDPShares">-311.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001415"
      unitRef="USDPShares">-311.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001417">&lt;p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zd9fOLKSJFZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Potentially
dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zY4MRGeQVVY2" style="display: none"&gt;Schedule of Potentially Dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_zV10JSOHLKea" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zeILSlclRqT9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zdnHo0T96T39" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options issued under the
    2021 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;89,406&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,775&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zVRiwiOdXMG3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock purchase
    warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;833,684&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65,559&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zjmCn74DfEne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;923,090&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70,334&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zNcCUuBWj5El" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Antidilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;923,090&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;70,334&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember16241843"
      decimals="INF"
      id="Fact001419"
      unitRef="Shares">89406</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember16241859"
      decimals="INF"
      id="Fact001420"
      unitRef="Shares">4775</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001422"
      unitRef="Shares">833684</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001423"
      unitRef="Shares">65559</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001425"
      unitRef="Shares">923090</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001426"
      unitRef="Shares">70334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001428"
      unitRef="Shares">923090</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001429"
      unitRef="Shares">70334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001431">&lt;p id="xdx_80B_eus-gaap--CollaborativeArrangementDisclosureTextBlock_znGATMQCr4F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(16)
&lt;span id="xdx_82A_zyvm1lmAsB9b"&gt;License Agreement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;CTx
has a licensing agreement with a company related to the patents and licensed know-how for use in the development of CTx-1301, CTx-1302,
and CTx-2103. CTx will pay the following upon the occurrence of the following milestone events:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_909_ecustom--MilestonePayment_c20240101__20241231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__us-gaap--VestingAxis__custom--PhaseThreeClinicalTrialMember_z8scubQJII85" title="Milestone payments"&gt;250,000&lt;/span&gt; Milestone payment
    upon dosing of first patient in a Phase 3 Clinical Trial for each product in the field, payable on a per product basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_905_ecustom--MilestonePayment_c20240101__20241231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__us-gaap--VestingAxis__custom--NewDrugApplicationMember_zLQi6DtszRlk" title="Milestone payment"&gt;250,000&lt;/span&gt; Milestone payment
    upon licensee filing of new drug application for each product in the field, payable on a per product basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_903_ecustom--MilestonePayment_c20240101__20241231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__us-gaap--VestingAxis__custom--CTxOneThreeZeroOneAndCTxOneThreeZeroTwoMember_zL3vhGz8rWlh" title="Milestone payment"&gt;250,000&lt;/span&gt; Milestone payment
    for CTx-1301 and CTx-1302 and $&lt;span id="xdx_907_ecustom--MilestonePayment_c20240101__20241231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__us-gaap--VestingAxis__custom--CTxTwoOneZeroThreeMember_zDt81Uv1rTlc" title="Milestone payment"&gt;500,000&lt;/span&gt; Milestone payment for CTx-2103 upon receipt of first marketing approval from the FDA, payable
    on a per product basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_900_ecustom--MilestonePayment_c20240101__20241231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__us-gaap--VestingAxis__custom--CTxTwoOneZeoThreeMember_z0FVVHElQfWd" title="Milestone payment"&gt;250,000&lt;/span&gt; Milestone payment
    for CTx-2103 upon receipt of first marketing approval from the EMA (European Medicines Agency)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
early 2023, the Company paid the first milestone payment as the first patient in a CTx-1301 Phase 3 Clinical Trial was dosed. The Company
has not recorded any expense relating to the other milestones for any other product as it has not deemed them probable of occurring as
of December 31, 2024.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <CING:MilestonePayment
      contextRef="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember_custom_PhaseThreeClinicalTrialMember"
      decimals="0"
      id="Fact001433"
      unitRef="USD">250000</CING:MilestonePayment>
    <CING:MilestonePayment
      contextRef="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember_custom_NewDrugApplicationMember"
      decimals="0"
      id="Fact001435"
      unitRef="USD">250000</CING:MilestonePayment>
    <CING:MilestonePayment
      contextRef="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember_custom_CTxOneThreeZeroOneAndCTxOneThreeZeroTwoMember"
      decimals="0"
      id="Fact001437"
      unitRef="USD">250000</CING:MilestonePayment>
    <CING:MilestonePayment
      contextRef="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember_custom_CTxTwoOneZeroThreeMember"
      decimals="0"
      id="Fact001439"
      unitRef="USD">500000</CING:MilestonePayment>
    <CING:MilestonePayment
      contextRef="From2024-01-012024-12-31_us-gaap_LicensingAgreementsMember_custom_CTxTwoOneZeoThreeMember"
      decimals="0"
      id="Fact001441"
      unitRef="USD">250000</CING:MilestonePayment>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001443">&lt;p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zGj9siOm90u8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(17)
&lt;span id="xdx_82E_z6C2D2Hc4knf"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
former general counsel of the Company is a partner with a law firm providing office facilities space that was leased by the Company.
Rental expense incurred by the Company to the law firm was $&lt;span id="xdx_90E_eus-gaap--OperatingCostsAndExpenses_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zOzDde1v1rQh" title="Rental expense"&gt;36,000&lt;/span&gt; in 2023, which approximates fair value. As of December 31, 2023, the
Company had no outstanding amounts payable under this lease and the lease expired on December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
member of the Company&#x2019;s Board of Directors, Peter Werth, is the manager of WFIA, the entity which provided $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zZrv4NMxOVh5" title="Debt financing amount"&gt;8.0&lt;/span&gt; million in debt
financing to the Company, $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230930__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zBJxZqLqdnQk" title="Debt financing amount"&gt;5.0&lt;/span&gt; million of which was converted to equity in September 2023 and the remaining $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WerthFamilyInvestmentAssociatesLLCMember_zznip602smr2" title="Principal amount"&gt;3.0&lt;/span&gt; million was converted
to equity in January 2024, as described in Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001445"
      unitRef="USD">36000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-09-30_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="-5"
      id="Fact001447"
      unitRef="USD">8000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-09-30_us-gaap_DebtMember_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="-5"
      id="Fact001449"
      unitRef="USD">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-31_custom_WerthFamilyInvestmentAssociatesLLCMember"
      decimals="-5"
      id="Fact001451"
      unitRef="USD">3000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001453">&lt;p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zn4o120Nnfg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(18)
&lt;span id="xdx_82E_zdmmDXN4RIw6"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Management
evaluated events that occurred subsequent to December 31, 2024 through March 27, 2025, which is the date the financial statements
were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;From
January through March 27, 2025, the Company sold &lt;span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z96B3ZusKWwf" title="Sale of stock, number of shares issued in transaction"&gt;142,685&lt;/span&gt; shares of common stock under the ATM Agreement, for net proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBU8B3VcFl5f" title="Proceeds from issuance of common stock"&gt;776,091&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;From
January through March 27, 2025, the Company sold &lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--LincolnParkPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zntSemdj9YV2" title="Sale of stock, number of shares issued in transaction"&gt;223,409&lt;/span&gt; shares of common stock under the Lincoln Park Purchase Agreement, for net proceeds
of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--LincolnParkPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zq3FZX8U9qM2" title="Proceeds from issuance of common stock"&gt;899,989&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001455"
      unitRef="Shares">142685</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001457"
      unitRef="USD">776091</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_LincolnParkPurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001459"
      unitRef="Shares">223409</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_LincolnParkPurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001461"
      unitRef="USD">899989</us-gaap:ProceedsFromIssuanceOfCommonStock>
</xbrl>
